You Searched For:
novartis

  • …Campbell Murray, managing director of Novartis Venture Funds and chairman of…Ebb & Flow. He added that Novartis Venture Funds hired its own…2008. Novartis Venture and Venture Investors led the…
  • …clean safety profile. Novartis AG's Glavus vildagliptin was approved in Europe…marketed DPP-4 inhibitors. For the same period, Novartis recorded $76 million in sales of Galvus, while…
  • …sanofi-aventis Group (Euronext:SAN; NYSE:SNY). Momenta and partner Sandoz, the generics unit of Novartis AG (NYSE:NVS; SIX:NOVN), submitted the ANDA in 2005 and received a not…
  • BioCentury on BioBusiness, Cover Story
    …Inc. Novartis AG (NYSE:NVS; SIX:NOVN) $120M…Speedel Novartis AG (NYSE:NVS; SIX:NOVN) $998M…aliskiren, which was already marketed by Novartis; other renin inhibitors in development to…
  • BioCentury on BioBusiness, Strategy
    …Inc. Novartis AG (NYSE:NVS; SIX:NOVN) $120M…Speedel Novartis AG (NYSE:NVS; SIX:NOVN) $998M…aliskiren, which was already marketed by Novartis; other renin inhibitors in development to…
  • BioCentury on BioBusiness, Analyst Picks & Changes
    …Ritalin LA methylphenidate, which is marketed by Novartis AG (NYSE:NVS; SIX:NOVN) and uses…Elan's drug delivery technology. Gilenia from Novartis has a Sept. 21 PDUFA date. Infinity…
  • While it may be ironic, it has taken the intervention of activist investors to bring in a quintessential biotech CEO, who nonetheless will be tasked for reviving the company's commercial performance while setting an R&D…
  • While it may be ironic, it has taken the intervention of activist investors to bring in a quintessential biotech CEO, who nonetheless will be tasked for reviving the company's commercial performance while setting an R&D…
  • BioCentury on BioBusiness, Finance
    Novartis AG (NYSE:NVS; SIX:NOVN…Genome Sciences Inc. (NASDAQ:HGSI)/ Novartis AG (NYSE:NVS; SIX:NOVN…Human Genome Sciences Inc. (NASDAQ:HGSI)/ Novartis AG (NYSE:NVS; SIX:NOVN) Says…
  • BioCentury on BioBusiness, Finance
    …NYSE:BMY) Ipilimumab Advanced melanoma Submit BLA Mid-2010 Bristol-Myers Squibb Co. (NYSE:BMY)/Novartis AG (NYSE:NVS; SIX:NOVN) Ilaris canakinumab Gout Submit regulatory applications 2H10 BTG plc…
  • BioCentury on BioBusiness, Finance
    …NYSE:MRK) 10.3 9.1 5.6% 1.8 1.6 Novartis AG (NYSE:NVS; SIX:NOVN) 10.5 10.1 3.8% 2.8 2.7 Pfizer Inc…
  • …collaboration with Vectura Group plc. Novartis AG has rights to NVA237…and as a component of Novartis' QVA149, a fixed-dose combination…Japan Novartis AG (NYSE:NVS; SIX:NOVN), Basel…
  • …BLA last November, and partner Novartis AG submitted an MAA in…EMA expressed similar concerns to Novartis, which withdrew its MAA in…Md. Novartis AG (NYSE:NVS; SIX:NOVN), Basel…
  • Multinational pharmas in Brazil are building on the back of a government healthcare scheme and distribution channels that favor generics and OTC products. Companies that want to do more than sell generics also need …
  • Multinational pharmas in Brazil are building on the back of a government healthcare scheme and distribution channels that favor generics and OTC products. Companies that want to do more than sell generics also need …
  • BioCentury on BioBusiness, Analyst Picks & Changes
    …signs of efficacy based on interim data reported in December (see BioCentury, Dec. 21, 2009). Novartis AG (NYSE:NVS; SIX:NOVN) has an option to in-license the recombinant subunit…
  • …the program to commercialization. Existing investors Healthcare Ventures, Fidelity Biosciences, TPG Biotechnology, Alta Partners, and Novartis Venture Funds also participated. FAP is a progressive neurodegen-erative disorder…
  • BioCentury on BioBusiness, Product Discovery & Development
    …The proposition for Zalbin albinterferon alfa-2b from Human Genome Sciences Inc. (NASDAQ:HGSI) and Novartis AG (NYSE:NVS; SIX:NOVN) has always been that its longer half-life should…
  • …recommendation to approve fingolimod from Novartis AG as the first oral…Novartis originally developed fingolimod to treat…renal program was still ongoing, Novartis began investigating the utility of…
  • …recommendation to approve fingolimod from Novartis AG as the first oral…Novartis originally developed fingolimod to treat…renal program was still ongoing, Novartis began investigating the utility of…
  • …development at Amgen. Novartis AG's Zometa is a bisphosphonate that attaches…apoptosis and prevents the cells from resorbing bone. Novartis posted $375 million in worldwide sales for Zometa…
  • BioCentury on BioBusiness, Cover Story
    …System Drugs Advisory Committee voted 25-0 that 0.5 mg/day of fingolimod from Novartis AG (NYSE:NVS; SIX:NOVN) was effective at reducing the clinical exacerbations of multiple…
  • BioCentury on BioBusiness, Cover Story
    …Drugs Advisory Committee to vote on nine questions related to the approvability of fingolimod from Novartis AG (NYSE:NVS; SIX:NOVN) to treat patients with relapsing-remitting multiple sclerosis (RRMS…
  • BioCentury on BioBusiness, Regulation
    …System Drugs Advisory Committee voted 25-0 that 0.5 mg/day of fingolimod from Novartis AG (NYSE:NVS; SIX:NOVN) was effective at reducing the clinical exacerbations of multiple…
  • BioCentury on BioBusiness, Regulation
    …Drugs Advisory Committee to vote on nine questions related to the approvability of fingolimod from Novartis AG (NYSE:NVS; SIX:NOVN) to treat patients with relapsing-remitting multiple sclerosis (RRMS…
  • …hepatitis C (HCV), seasonal influenza, tuberculosis, cancers and allergies. The flu program is partnered with Novartis AG, the TB program is partnered with Pfizer Inc., while GlaxoSmithKline plc has licensed…
  • BioCentury on BioBusiness, Cover Story
    …technology Ixiaro vaccine (IC51), partnered w/ Novartis AG; CSL Ltd.; Biological E. Ltd…Speedel, acquired by Novartis AG (NYSE:NVS; SIX:NOVN…disorders Tekturna/Rasilez aliskiren [Novartis; Ciba-Geigy] 2009…
  • …hepatitis C (HCV), seasonal influenza, tuberculosis, cancers and allergies. The flu program is partnered with Novartis AG, the TB program is partnered with Pfizer Inc., while GlaxoSmithKline plc has licensed…
  • BioCentury on BioBusiness, Finance
    …technology Ixiaro vaccine (IC51), partnered w/ Novartis AG; CSL Ltd.; Biological E. Ltd…Speedel, acquired by Novartis AG (NYSE:NVS; SIX:NOVN…disorders Tekturna/Rasilez aliskiren [Novartis; Ciba-Geigy] 2009…
  • BioCentury on BioBusiness, Cover Story
    …plc (LSE:AZN; NYSE:AZN) $210 $53.9 Biology: DNA repair Speedel Novartis AG (NYSE:NVS; SIX:NOVN) $1,000 $275.3 Specialty pharma: cardiovascular and metabolic disorders Other M…
  • BioCentury on BioBusiness, Finance
    …plc (LSE:AZN; NYSE:AZN) $210 $53.9 Biology: DNA repair Speedel Novartis AG (NYSE:NVS; SIX:NOVN) $1,000 $275.3 Specialty pharma: cardiovascular and metabolic disorders Other M…
  • BioCentury on BioBusiness, Emerging Company Profiles
    …None Number of employees: 24 Funds raised: $34.1 million Investors: Novo A/S, Novartis Venture Funds, Roche Venture Fund and SR One CEO: Lawrence Blatt Patents: Five issued, including…
  • …marketed for wet age-related macular degeneration (AMD) by Roche's Genentech Inc. unit and Novartis AG. The mAb fragment against VEGF inhibits formation of blood vessels. Results from the…
  • …lead candidate TG4010 (MVA-MUC1-IL2) in non-small cell lung cancer (NSCLC). In March, Novartis AG (NYSE:NVS; SIX:NOVN) paid $10 million for an option to TG4010 for…
  • …based in Europe: AstraZeneca plc (LSE:AZN; NYSE:AZN); GlaxoSmithKline plc (LSE:GSK; NYSE:GSK); Novartis AG (NYSE:NVS; SIX:NOVN); sanofi-aventis Group (Euronext:SAN; NYSE:SNY); Novo Nordisk…
  • …of $170M Merck KGaA (Xetra:MRK) $18,162 $634 4% NA NA Novartis AG (NYSE:NVS; SIX:NOVN) $120,268 -$2,775 -2% NA Impact is "manageable within our guidance…
  • BioCentury on BioBusiness, Product Discovery & Development
    …to treat advanced NSCLC in poor performance status women in 1H07 9/18 - Grants Novartis AG (NYSE:NVS; SIX:NOVN) a worldwide license to co-develop and commercialize Opaxio 11…
  • …Last week's deal with Novartis AG, plus a collaboration late…week's deal, Array granted Novartis exclusive, worldwide rights to co…to two undisclosed cancer indications. Novartis will be responsible for all…
  • BioCentury on BioBusiness, Finance
    Ebb & Flow: The Bite of Reform EPS watch At least 14 profitable biotechs and pharmas reported earnings last week. Gilead Inc. (NASDAQ:GILD) lost $3.6 billion in market value after it lowered its FY10 guidance to …
  • BioCentury on BioBusiness, Analyst Picks & Changes
    …due to reduced "expectations for dilutive equity issuances in 2010 and beyond" after Array granted Novartis AG (NYSE:NVS; SIX:NOVN) exclusive, worldwide rights to co-develop and commercialize MEK…
  • BioCentury on BioBusiness, Finance
    …Sciences Inc. (NASDAQ:GILD) and Novartis AG (NYSE:NVS; SIX:NOVN…1 billion, up 35%, while Novartis' top line is expected to…45% Novartis AG (NYSE:NVS; SIX:NOVN) 4…
  • BioCentury on BioBusiness, Analyst Picks & Changes
    …50 from $10 on the company's improved financial position following out-licensing deals with Novartis AG (NYSE:NVS; SIX:NOVN) for INCB18424 and Eli Lilly and Co. (NYSE:LLY…
  • …14, with the first day of trading slated for April 21. Existing investors Truffle Capital; Novartis Venture Funds; and OTC have committed to subscribe for €2.5 million ($3…
  • …the way it and partner Novartis AG have run development for…for the $75 million that Novartis paid up front in 2007…obviously on that basis that Novartis, like us, took the view…
  • …example of the firm's strategic partnering model is anti-infective company Protez Pharmaceuticals Inc. Novartis AG (NYSE:NVS; SWX:NOVN) acquired the former portfolio company in 2008 for $100…
  • BioCentury on BioBusiness, Finance
    …down in the last week of the quarter. Antisoma fell 75% last Monday after partner Novartis AG (NYSE:NVS; SIX:NOVN) halted a Phase III trial of ASA404 in non…
  • BioCentury on BioBusiness, Cover Story
    …Company Omnitrope/ Sandoz International GmbH, a unit of Novartis AG(NYSE:NVS; SIX:NOVN) Valtropin/BioPartners Binocrit…Epoetin Alfa Hexal/ Hexal AG, a unit of Novartis Filgrastim/ratiopharm GmbH…
  • …treat advanced renal cell carcinoma (RCC) and GIST. Novartis AG markets Gleevec for GIST, chronic myelogenous leukemia…MRK), Darmstadt, Germany Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland OSI…
  • BioCentury on BioBusiness, Regulation
    …Company Omnitrope/ Sandoz International GmbH, a unit of Novartis AG(NYSE:NVS; SIX:NOVN) Valtropin/BioPartners Binocrit…Epoetin Alfa Hexal/ Hexal AG, a unit of Novartis Filgrastim/ratiopharm GmbH…
  • …markets Advair salmeterol/fluticasone and Serevent salmeterol; AstraZeneca plc, which markets Symbicort formoterol/budesonide; and Novartis AG, which markets Foradil formoterol. Salmeterol and formoterol are LABAs; fluticasone…
  • …markets Advair salmeterol/fluticasone and Serevent salmeterol; AstraZeneca plc, which markets Symbicort formoterol/budesonide; and Novartis AG, which markets Foradil formoterol. Salmeterol and formoterol are LABAs; fluticasone…
  • BioCentury on BioBusiness, Cover Story
    …Mkt GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) Serevent salmeterol Mkt Merck & Co. Inc. (NYSE:MRK)/ Novartis AG (NYSE:NVS; SIX:NOVN) Foradil formoterol Mkt Vectura Group plc (LSE:VEC) Formoterol…
  • …to begin later this year. Three major shareholders have committed to subscribe to the offering: Novartis Venture Fund (up to €1 million); Truffle Capital (up to €1 million…
  • …Sandoz, will receive a $9.5 million payment next quarter from the generics unit of Novartis AG (NYSE:NVS; SIX:NOVN). Sandoz also will put in place a loan facility…
  • …and Janumet sitagliptin/metformin from Merck & Co. Inc.; Galvus vildagliptin and Eucreas vildagliptin/metformin from Novartis AG; and Onglyza saxagliptin from Bristol-Myers Squibb Co. Subtracting the $1.3 billion…
  • BioCentury on BioBusiness, Regulation
    …Mkt GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) Serevent salmeterol Mkt Merck & Co. Inc. (NYSE:MRK)/ Novartis AG (NYSE:NVS; SIX:NOVN) Foradil formoterol Mkt Vectura Group plc (LSE:VEC) Formoterol…
  • Ebb & Flow

    BioCentury on BioBusiness, Finance
    …€18.51 on Wednesday after granting Novartis AG (NYSE:NVS; SIX:NOVN) an option…for a $10 million option fee. If Novartis exercises its option, Transgene would be eligible…
  • BioCentury on BioBusiness, Strategy
    …testing to treat RSV and was partnered with Novartis AG; it was still listed as a partnered…London, U.K. Novartis AG, (NYSE:NVS; SIX:NOVN), Basel, Switzerland Rigel…
  • Ebb & Flow

    BioCentury on BioBusiness, Finance
    …Corp. (NASDAQ:GENZ), Shire plc (LSE:SHP; NASDAQ:SHPGY), GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), Novartis AG (NYSE:NVS; SIX:NOVN); and Pfizer Inc. (NYSE:PFE) have "all shown interest…
  • BioCentury on BioBusiness, Emerging Company Profiles
    …marketed by Pfizer Inc. and Eisai Co. Ltd., while Novartis AG markets Exelon. COMPANIES AND INSTITUTIONS MENTIONED…4523), Tokyo, Japan Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Pfizer…
  • BioCentury on BioBusiness, Cover Story
    …2001 Novartis AG (NYSE:NVS; SIX:NOVN) Compounds…Novartis AG (NYSE:NVS; SIX:NOVN…1999 Novartis AG (NYSE:NVS; SIX:NOVN) Identify…
  • BioCentury on BioBusiness, Analyst Picks & Changes
    …sanofi-aventis Group (Euronext:SAN; NYSE:SNY), is partnered with Sandoz, the generics unit of Novartis AG (NYSE:NVS; SIX:NOVN). Novavax Inc. (NASDAQ:NVAX) Piper Jaffray Edward Tenthoff Price…
  • BioCentury on BioBusiness, Product Discovery & Development
    Novartis AG has built a competitive…in Phase IIb trials, while Novartis' NIM811, an oral small molecule…Global Head of Development for Novartis' Immunology & Infectious Diseases Franchise, told…
  • BioCentury on BioBusiness, Product Discovery & Development
    …or overall survival (OS). Going against Zometa Amgen went head to head with Zometa from Novartis AG using an identical development program because Zometa is the standard of care for…
  • BioCentury on BioBusiness, Product Discovery & Development
    …below 1 represents a benefit to patients given denosumab over Zometa, which is marketed by Novartis AG (NYSE:NVS; SIX:NOVN). (A) Excludes breast and prostate cancer; (B) Primary endpoint…
  • BioCentury on BioBusiness, Strategy
    …experience Novartis' new organization NovartisNovartis AG (NYSE:NVS; SIX:NOVN…Institutes for Biomedical Research; NCH = Novartis Consumer Health; Source:Novartis AG…
  • BioCentury on BioBusiness, Strategy
    Novartis ins and outs …year tenure as CEO of Novartis AG (NYSE:NVS; SIX:NOVN…came from healthcare. According to Novartis, of $47.5 billion in…
  • BioCentury on BioBusiness, Strategy
    …57 flavors of experience Novartis deal flow New CEO Joe Jimenez…2009 was a record year for in-licensing, as Novartis AG (NYSE:NVS; SIX:NOVN) brought in six compounds…
  • BioCentury on BioBusiness, Strategy
    Novartis ins and outs …Novartis' new organization …Novartis deal flow …
  • BioCentury on BioBusiness, Regulation
    FDA drug safety guidance begs questions about enforcement and privacy.
  • BioCentury on BioBusiness, Cover Story
    …experience Novartis' new organization NovartisNovartis AG (NYSE:NVS; SIX:NOVN…Institutes for Biomedical Research; NCH = Novartis Consumer Health; Source:Novartis AG…
  • BioCentury on BioBusiness, Cover Story
    Novartis ins and outs …year tenure as CEO of Novartis AG (NYSE:NVS; SIX:NOVN…came from healthcare. According to Novartis, of $47.5 billion in…
  • BioCentury on BioBusiness, Cover Story
    …57 flavors of experience Novartis deal flow New CEO Joe Jimenez…2009 was a record year for in-licensing, as Novartis AG (NYSE:NVS; SIX:NOVN) brought in six compounds…
  • BioCentury on BioBusiness, Cover Story
    Novartis ins and outs …Novartis' new organization …Novartis deal flow …
  • BioCentury on BioBusiness, Finance
    …currency exchange impact. Novartis AG (NYSE:NVS; SIX:NOVN) $1.15 $1…and 19% to $2.1B over 4Q08, respectively. Novartis said swine influenza A (H1N1) vaccines and adjuvants…
  • Corporate Profile

    BioCentury on BioBusiness, Emerging Company Profiles
    …Discovery Founded: 2007 by Dragan Grabulovski, Julian Bertschinger and Novartis Venture Fund University collaborators: Swiss Federal…Funds raised: Undisclosed Investors: Novartis Venture Fund; Edmond de Rothschild Investment Partners; Ventech…
  • BioCentury on BioBusiness, Emerging Company Profiles
    …A round in 2Q10. The company has raised an undisclosed sum in seed financing from Novartis Venture Fund; Edmond de Rothschild Investment Partners; Ventech and MP Healthcare Venture Management Inc…
  • BioCentury on BioBusiness, Finance
    …Celgene Corp. (NASDAQ:CELG) and Novartis AG (NYSE:NVS; SIX:NOVN…revenues to $740 million, while Novartis is expected to report a…3% Novartis AG (NYSE:NVS; SIX:NOVN) 1…
  • BioCentury on BioBusiness, Finance
    …therapy at a price comparable to what Novartis AG charged for Zelnorm tegaserod when it…million after five years of promotion. But Novartis (NYSE:NVS; SIX:NOVN) withdrew it in…
  • BioCentury on BioBusiness, Product Discovery & Development
    …are treated with Tobi tobramycin, an aminoglycoside from Novartis AG that is the only approved inhaled antibiotic…San Francisco, Calif. Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland sanofi…
  • BioCentury on BioBusiness, Strategy
    …346 22% Merck & Co. Inc. (NYSE:MRK) $5,231 $17,334 30% Novartis AG (NYSE:NVS; SIX:NOVN) $7,339 $31,341 23% Pfizer Inc. (NYSE:PFE) $10,377 $33…
  • BioCentury on BioBusiness, Cover Story
    …CSL)/Intercell AG (VSE:ICLL)/ Novartis AG (NYSE:NVS; SIX:NOVN…Novartis AG (NYSE:NVS; SIX:NOVN…Novartis AG (NYSE:NVS; SIX:NOVN…
  • BioCentury on BioBusiness, Finance
    …CSL)/Intercell AG (VSE:ICLL)/ Novartis AG (NYSE:NVS; SIX:NOVN…Novartis AG (NYSE:NVS; SIX:NOVN…Novartis AG (NYSE:NVS; SIX:NOVN…
  • BioCentury on BioBusiness, Cover Story
    …2010 Genentech Inc./Novartis AG (NYSE:NVS; SIX:NOVN)/Roche…Corp. (Tokyo:4508; Osaka:4508)/ Novartis AG (NYSE:NVS; SIX:NOVN…2Q10 Novartis AG (NYSE:NVS; SIX:NOVN) AIN457…
  • BioCentury on BioBusiness, Finance
    …2010 Genentech Inc./Novartis AG (NYSE:NVS; SIX:NOVN)/Roche…Corp. (Tokyo:4508; Osaka:4508)/ Novartis AG (NYSE:NVS; SIX:NOVN…2Q10 Novartis AG (NYSE:NVS; SIX:NOVN) AIN457…
  • BioCentury on BioBusiness, Cover Story
    …Genentech Inc./Roche(SIX:ROG; OTCQX:RHHBY)/Novartis AG (NYSE:NVS; SIX:NOVN) Lucentis ranibizumab…Genentech Inc./Roche (SIX:ROG; OTCQX:RHHBY)/Novartis AG (NYSE:NVS; SIX:NOVN) Xolair omalizumab…
  • BioCentury on BioBusiness, Finance
    …Genentech Inc./Roche(SIX:ROG; OTCQX:RHHBY)/Novartis AG (NYSE:NVS; SIX:NOVN) Lucentis ranibizumab…Genentech Inc./Roche (SIX:ROG; OTCQX:RHHBY)/Novartis AG (NYSE:NVS; SIX:NOVN) Xolair omalizumab…
  • BioCentury on BioBusiness, Cover Story
    …U.S. $7.3 (NASDAQ:MBRK) extended-release tablets secondary to Streptococcus pyogenes Novartis AG (NYSE:NVS; Extavia interferon beta-1b Early and relapsing forms of multiple EU $26.0…
  • BioCentury on BioBusiness, Finance
    …U.S. $7.3 (NASDAQ:MBRK) extended-release tablets secondary to Streptococcus pyogenes Novartis AG (NYSE:NVS; Extavia interferon beta-1b Early and relapsing forms of multiple EU $26.0…
  • BioCentury on BioBusiness, Cover Story
    …pressure goals Bristol-Myers Squibb Co. (NYSE:BMY)/ Novartis AG (NYSE:NVS; SIX:NOVN) EC approves Ilaris…postherpetic neuralgia (PHN) Novartis AG (NYSE:NVS; SIX:NOVN) EC approves Exforge…
  • BioCentury on BioBusiness, Finance
    …pressure goals Bristol-Myers Squibb Co. (NYSE:BMY)/ Novartis AG (NYSE:NVS; SIX:NOVN) EC approves Ilaris…postherpetic neuralgia (PHN) Novartis AG (NYSE:NVS; SIX:NOVN) EC approves Exforge…
  • BioCentury on BioBusiness, Strategy
    …s deal with GlaxoSmithKline plc. (A) Novartis AG has option to in-license…countries Novartis AG (NYSE:NVS; SIX:NOVN); CSL…II Novartis Pandemic…
  • BioCentury on BioBusiness, Strategy
    …has three other pharma partners: Novartis AG, Merck & Co. Inc. and…Under the Novartis deal, Intercell may choose to…profits up to 50/50. Novartis, which owns just under 15…
  • BioCentury on BioBusiness, Product Discovery & Development
    …Phase III data presented by Novartis AG at the American Society…diagnosed Philadelphia chromosome-positive CML. Novartis plans to submit an sNDA…as tyrosine kinase inhibitors, including Novartis' Gleevec imatinib and Tasigna, were…
  • BioCentury on BioBusiness, Politics and Policy
    …example, Andrin Oswald, CEO of Novartis AG's Vaccines and Diagnostics…company and FDA have stymied Novartis from seeking U.S. approval…on large-scale studies that Novartis felt were scientifically unnecessary and…
  • BioCentury on BioBusiness, Analyst Picks & Changes
    …to $15 from $12 after Incyte granted Novartis AG (NYSE:NVS; SIX:NOVN) ex-U…from partner Sandoz, the generics unit of Novartis AG (NYSE:NVS; SIX:NOVN). Amin expects…
  • BioCentury on BioBusiness, Cover Story
    …Co. and Tasigna nilotinib from Novartis AG available to patients with…resistant to or intolerant of Novartis' Gleevec imatinib (Glivec in Europe…also isn't surprising that Novartis and BMS haven't…
  • BioCentury on BioBusiness, Analyst Picks & Changes
    …a slow country-by-country launch, not to lower demand or a smaller sales potential. Novartis AG (NYSE:NVS; SIX:NOVN) has rights to market the vaccine in the U…
  • BioCentury on BioBusiness, Product Discovery & Development
    …and both have limitations because of side effects. Novartis AG suspended U.S. marketing of Zelnorm tegaserod…ALM), Barcelona, Spain Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Sucampo…
  • BioCentury on BioBusiness, Emerging Company Profiles
    …Clinical status: Discovery Founded: 2009 by Atlas Venture, Novartis Venture Fund, Sir Gregory Winter, Christian Heinis and…Funds raised: Undisclosed Investors: Atlas Venture, Novartis Venture Fund CEO: John Tite…
  • BioCentury on BioBusiness, Product Discovery & Development
    …12286 against RKI983, a Rho kinase inhibitor from Novartis AG and Senju Pharmaceutical Co. Ltd., and found…Durham, N.C. Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Pfizer…
  • BioCentury on BioBusiness, Finance
    Ebb & Flow EPS watch At least 14 biotechs and pharmas reported earnings last week. Genzyme Corp. (NASDAQ:GENZ) shed $1 billion in market cap after reporting 3Q09 non-GAAP EPS of $0.31 and 3Q09 revenues of $1.06 …
  • Ebb & Flow

    BioCentury on BioBusiness, Finance
    …up front, plus milestones, after Novartis AG (NYSE:NVS; SIX:NOVN…Last week, Novartis paid $200 million up front…a $5 million milestone to Novartis in 2007. The biotech also…
  • BioCentury on BioBusiness, Finance
    …Co. Inc. (NYSE:MRK) 10/22 Pre $0.83 $0.80 4% Novartis AG (NYSE:NVS; SIX:NOVN) 10/22 Pre $0.98 $0.92 7% Schering-Plough Corp. (NYSE…
  • BioCentury on BioBusiness, Product Discovery & Development
    …treat relapsing-remitting MS; and Novartis AG reported Phase III data…Data from Novartis' Phase III FREEDOMS trial showed…Novartis plans to submit regulatory applications…
  • BioCentury on BioBusiness, Product Discovery & Development
    …kg cladribine (456) 0.15 55% 31% Placebo (437) 0.33 Fingolimod from Novartis AG (NYSE:NVS; SIX:NOVN)/Mitsubishi Tanabe Pharma Corp. (Tokyo:4508; Osaka:4508) 2-year Ph…
  • BioCentury on BioBusiness, Finance
    …H1N1) Novartis AG (NYSE:NVS; SIX:NOVN) EC…Novartis AG (NYSE:NVS; SIX:NOVN…MS) Novartis AG (NYSE:NVS; SIX:NOVN) FDA…
  • BioCentury on BioBusiness, Finance
    …Metastatic HER2 negative breast cancer Submit sBLA YE09 Genentech Inc./Roche (SIX:ROG; OTCQX:RHHBY)/Novartis AG (NYSE:NVS; SIX:NOVN) Xolair omalizumab Moderate to severe persistent asthma in patients…
  • BioCentury on BioBusiness, Strategy
    …its pulmonary drug delivery business to Novartis AG last year for $115 million…The deal with Novartis did not include a pair…Calif. Novartis AG (NYSE:NVS; SIX:NOVN), Basel…
  • BioCentury on BioBusiness, Product Discovery & Development
    …of Lucentis ranibizumab to treat wet AMD from Novartis AG and Roche's Genentech Inc. unit was…City, N.J. Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Roche…
  • BioCentury on BioBusiness, Finance
    …investors included SV Life Sciences, Clarus Ventures, Novartis Bioventures, BioMedinvest and VI Partners. Brahms lullaby…investors include Symbion; Sunstone Capital; Dansk Innovation; Novartis Venture; Astellas Ventures; and Ventureast. It has…
  • BioCentury on BioBusiness, Emerging Company Profiles
    …coli that is in preclinical development and partnered with Novartis AG. "I decided to go…S.A., Paris, France Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Pfizer Inc…
  • BioCentury on BioBusiness, Strategy
    …When Novartis AG sold its Betaseron manufacturing…for $110 million in 2007, Novartis could have sought to co…the multiple sclerosis drug. Instead, Novartis chose to get approval of…
  • BioCentury on BioBusiness, Cover Story
    …fragmentation and damage to PML-RAR alpha fusion protein Ph III (A) Novartis AG (NYSE:NVS; SIX:NOVN) Midostaurin (PKC412) Protein kinase C (PKC) inhibitor Ph III (A) Eisai Co…
  • BioCentury on BioBusiness, Regulation
    …fragmentation and damage to PML-RAR alpha fusion protein Ph III (A) Novartis AG (NYSE:NVS; SIX:NOVN) Midostaurin (PKC412) Protein kinase C (PKC) inhibitor Ph III (A) Eisai Co…
  • BioCentury on BioBusiness, Emerging Company Profiles
    …Number of employees: 9 Funds raised: $21 million Investors: Triathlon Medical Ventures, Kearney Venture Partners, Novartis Venture Funds, Venture Investors LLC, American Venture Partners and Sigvion Capital CEO: Joseph…
  • BioCentury on BioBusiness, Product Discovery & Development
    …Roche's Genentech Inc. and Novartis AG co-market Xolair in…in the U.S., and Novartis markets the recombinant humanized mAb…K. Novartis AG (NYSE:NVS; SIX:NOVN), Basel…
  • BioCentury on BioBusiness, Product Discovery & Development
    …in mind, former European licensee Novartis AG stopped development in 2005…no longer competitive enough for Novartis to invest further resources." …it has different goals than Novartis, which already had Lescol fluvastatin…
  • BioCentury on BioBusiness, Regulation
    …changed, as the drug is generic and Novartis AG thus has little incentive to run…Sandoz International GmbH, now a unit of Novartis. The company voluntarily withdrew the product in…
  • BioCentury on BioBusiness, Regulation
    …meeting - CSL Ltd., GlaxoSmithKline plc, MedImmune, Novartis AG, and sanofi-aventis Group. There…panel. Novartis expects to have data in November…EUA. The Novartis trial is comparing an unadjuvanted monovalent…
  • BioCentury on BioBusiness, Analyst Picks & Changes
    …weaken its position in partnership discussions with Novartis AG (NYSE:NVS; SIX:NOVN). Idenix will…to the pharma in 3Q09, after which Novartis has 90 days to decide whether to…
  • Ebb & Flow

    BioCentury on BioBusiness, Finance
    …October. Avila option The Novartis Option Fund is ramping up to take advantage…he added. Skinner is joining the Avila board. Novartis Option Fund led the round as a new…
  • BioCentury on BioBusiness, Regulation
    …years >=18 years MedImmune Inc. (B) FluMist Live attenuated 2-49 years Novartis AG (NYSE:NVS; SIX:NOVN) Fluvirin Inactivated >=4 years sanofi-aventis Group (Euronext:SAN; NYSE:SNY) Fluzone…
  • BioCentury on BioBusiness, Strategy
    …Interleukin-1 (IL-1) Approved in U.S. and Switzerland to treat [Novartis AG (NYSE:NVS; SIX:NOVN)] children and adults with cryopyrin-associated periodic syndrome (CAPS); CHMP has issued…
  • BioCentury on BioBusiness, Product Discovery & Development
    …in the U.S. February's deal with Novartis AG for elinogrel, a reversible ADP receptor (P2Y12) antagonist…Station, N.J. Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Pfizer…
  • BioCentury on BioBusiness, Finance
    …4.45-$4.55. Figures include a negative foreign currency exchange impact Novartis AG (NYSE:NVS; SIX:NOVN) $0.85 $0.90 Beat by $0.05 -9% $42.39 $3…
  • BioCentury on BioBusiness, Analyst Picks & Changes
    …Zometa on the secondary endpoint of time to the first and subsequent on-study SREs. Novartis AG (NYSE:NVS; SIX:NOVN) markets Zometa (see "Denosumab Dreams," A15). Yang raised her…
  • Ebb & Flow

    BioCentury on BioBusiness, Finance
    …non-inferiority to Zometa zoledronic acid from Novartis AG (NYSE:NVS; SIX:NOVN), but denosumab…first tranche of a series B round. Novartis Bioventures led the round, with participation from…
  • BioCentury on BioBusiness, Finance
    …CKD) Intercell AG (VSE:ICLL)/ Novartis AG (NYSE:NVS; SIX:NOVN) EC…adults Novartis AG (NYSE:NVS; SIX:NOVN) FDA…NASDAQ:MEDX). Novartis AG (NYSE:NVS; SIX:NOVN) Japan approves…
  • BioCentury on BioBusiness, Finance
    …Inc. (NASDAQ:CTIC; Milan:CTIC)/ Novartis AG (NYSE:NVS; SIX:NOVN…Inc. (NASDAQ:CTIC; Milan:CTIC)/ Novartis AG (NYSE:NVS; SIX:NOVN…Genentech Inc. (B)/Novartis (NYSE:NVS; SIX:NOVN) …
  • BioCentury on BioBusiness, Cover Story
    …Lundbeck A/S (CSE:LUN) $3.2 (A) 6. Diovan valsartan Hypertension Novartis AG (NYSE:NVS; SIX:NOVN) $5.7 (B) 7. Aricept donepezil Dementia Eisai Co. Ltd. (Tokyo:4523…
  • BioCentury on BioBusiness, Politics and Policy
    …Lundbeck A/S (CSE:LUN) $3.2 (A) 6. Diovan valsartan Hypertension Novartis AG (NYSE:NVS; SIX:NOVN) $5.7 (B) 7. Aricept donepezil Dementia Eisai Co. Ltd. (Tokyo:4523…
  • BioCentury on BioBusiness, Regulation
    …organic anion urate transporter member 12 (SLC22A12) (URAT1) Treat gout Ph II Novartis AG (NYSE:NVS; SIX:NOVN)/Medarex Inc. (NASDAQ:MEDX) Ilaris canakinumab (ACZ885) Subcutaneous Human anti-IL-1…
  • DPP-4 face-off

    BioCentury on BioBusiness, Product Discovery & Development
    …7% [100 mg QD] (p<0.001) Galvus vildagliptin (mkt in EU) Novartis AG (NYSE:NVS; SIX:NOVN) Study 2303 (n=416); 24 wks 8.3% -0.73% [50 mg…
  • BioCentury on BioBusiness, Cover Story
    …acquired in 2007; Costa is the former president and CEO of the U.S. unit of Novartis AG. With only two votes in hand, the dissidents' ability to pursue…
  • BioCentury on BioBusiness, Finance
    …acquired in 2007; Costa is the former president and CEO of the U.S. unit of Novartis AG. With only two votes in hand, the dissidents' ability to pursue…
  • BioCentury on BioBusiness, Strategy
    …Last week, Elixir gave Novartis AG an exclusive option to…a potential tax incentive for Novartis to acquire the whole company…an undisclosed upfront payment from Novartis, as well as $12 million…
  • BioCentury on BioBusiness, Product Discovery & Development
    …synthetic acyclic guanine derivative prodrug of penciclovir from Novartis AG; and generic acyclovir. Each of these…Whitehouse Station, N.J. Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland sanofi-aventis…
  • Ebb & Flow

    BioCentury on BioBusiness, Finance
    …between Elixir Pharmaceuticals Inc. and Novartis AG (NYSE:NVS; SIX:NOVN…Last week's deal gives Novartis an exclusive option to acquire…Type II diabetes and obesity. Novartis also received an option for…
  • BioCentury on BioBusiness, Analyst Picks & Changes
    …FDA. An ANDA for M-Enoxaparin filed by Momenta's partner, the Sandoz unit of Novartis AG (NYSE:NVS; SIX:NOVN), is pending at the agency. He also said the…
  • BioCentury on BioBusiness, Product Discovery & Development
    …monthly, extended-release, injectable formulation. Novartis AG, which granted Vanda rights…12 million milestone payment to Novartis triggered by the FDA approval…which out-licensed iloperidone to Novartis, is eligible for a portion…
  • BioCentury on BioBusiness, Analyst Picks & Changes
    …thinks denosumab has only a 40% chance of being superior to Zometa zoledronic acid from Novartis AG (NYSE:NVS; SIX:NOVN) in Phase III trials to prevent skeletal-related events…
  • BioCentury on BioBusiness, Cover Story
    Product Development HCV cocktail party By Michael Flanagan & Stephen Hansen Staff Writers Interferons on Deck It is a given that HCV treatment will follow the same cocktail strategy used in HIV. The question is …
  • Interferons on Deck

    BioCentury on BioBusiness, Cover Story
    …formulation of long-acting native IFN alpha-2b Company Human Genome Sciences Inc. (NASDAQ:HGSI)/ Novartis AG (NYSE:NVS; SIX:NOVN) Biolex Therapeutics Inc. [Locteron uses controlled- release technology from…
  • BioCentury on BioBusiness, Product Discovery & Development
    Product Development HCV cocktail party By Michael Flanagan & Stephen Hansen Staff Writers Interferons on Deck It is a given that HCV treatment will follow the same cocktail strategy used in HIV. The question is …
  • Interferons on Deck

    BioCentury on BioBusiness, Product Discovery & Development
    …formulation of long-acting native IFN alpha-2b Company Human Genome Sciences Inc. (NASDAQ:HGSI)/ Novartis AG (NYSE:NVS; SIX:NOVN) Biolex Therapeutics Inc. [Locteron uses controlled- release technology from…
  • BioCentury on BioBusiness, Cover Story
    …head of vaccines research at Novartis AG. "…to a timetable provided by Novartis. "…additional one to two weeks," Novartis said. "That would bring us…
  • BioCentury on BioBusiness, Product Discovery & Development
    …head of vaccines research at Novartis AG. "…to a timetable provided by Novartis. "…additional one to two weeks," Novartis said. "That would bring us…
  • BioCentury on BioBusiness, Product Discovery & Development
    Product Development Palm needs alms By Aaron Bouchie Senior Writer NS5B inhibitor landscape To continue development of lead compound ANA598, Anadys Pharmaceuticals Inc. will have to convince potential partners …
  • Adjuvant Technologies

    BioCentury on BioBusiness, Cover Story
    …Aviv:NSVX) VaxiSome technology using ceramide carbamoyl spermine (CCS) mixed with cholesterol Novartis AG (NYSE:NVS; SIX:NOVN) MF59 adjuvant made of stable droplets of the oil squalene and two…
  • BioCentury on BioBusiness, Cover Story
    …V., part of Schering-Plough Corp. (NYSE:SGP) Avian and mammalian cells Novartis AG (NYSE:NVS; SIX:NOVN) MDCK cells Novavax Inc. (NASDAQ:NVAX) Insect cells Polymun Scientific Immunbiologische Forschung…
  • Adjuvant Technologies

    BioCentury on BioBusiness, Product Discovery & Development
    …Aviv:NSVX) VaxiSome technology using ceramide carbamoyl spermine (CCS) mixed with cholesterol Novartis AG (NYSE:NVS; SIX:NOVN) MF59 adjuvant made of stable droplets of the oil squalene and two…
  • BioCentury on BioBusiness, Product Discovery & Development
    …Inc. (NASDAQ:IDIX). Both are in Phase I. GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) and Novartis AG (NYSE:NVS; SIX:NOVN) are partnered to develop non-nucleoside HCV inhibitors. (A…
  • BioCentury on BioBusiness, Product Discovery & Development
    …V., part of Schering-Plough Corp. (NYSE:SGP) Avian and mammalian cells Novartis AG (NYSE:NVS; SIX:NOVN) MDCK cells Novavax Inc. (NASDAQ:NVAX) Insect cells Polymun Scientific Immunbiologische Forschung…
  • BioCentury on BioBusiness, Cover Story
    …to previous deals that allowed Novartis AG and Johnson & Johnson to…The Novartis and J&J deals for…the use of Lucentis from Novartis and Genentech Inc. for eligible…
  • BioCentury on BioBusiness, Regulation
    …to previous deals that allowed Novartis AG and Johnson & Johnson to…The Novartis and J&J deals for…the use of Lucentis from Novartis and Genentech Inc. for eligible…
  • Earnings On Deck

    BioCentury on BioBusiness, Finance
    …Amgen Inc. (NASDAQ:AMGN) 4/23 Post $1.15 $1.12 3% Novartis AG (NYSE:NVS; SIX:NOVN) 4/23 NA $0.86 $1.02 -16%…
  • BioCentury on BioBusiness, Product Discovery & Development
    Product Development Weight and see By Erin McCallister Senior Writer Weight loss comparisons There are now three obesity compounds in late-stage development with positive Phase III data, which means the number of…
  • BioCentury on BioBusiness, Analyst Picks & Changes
    …highly-dilutive financing. He thinks the company's NIC002, a nicotine addiction vaccine partnered with Novartis AG (NYSE:NVS; SIX:NOVN), is highly risky from a scientific point of view…
  • GAD pipeline

    BioCentury on BioBusiness, Cover Story
    …Ph III AstraZeneca AZD7325 GABA receptor subtype partial agonist Ph II Synosia Therapeutics AG/ Novartis AG (NYSE:NVS; SIX:NOVN) Rufinamide (SYN-111) Triazole derivative Ph II Sepracor Inc. (NASDAQ…
  • GAD pipeline

    BioCentury on BioBusiness, Regulation
    …Ph III AstraZeneca AZD7325 GABA receptor subtype partial agonist Ph II Synosia Therapeutics AG/ Novartis AG (NYSE:NVS; SIX:NOVN) Rufinamide (SYN-111) Triazole derivative Ph II Sepracor Inc. (NASDAQ…
  • 1Q approvals

    BioCentury on BioBusiness, Finance
    …CSL)/Intercell AG (VSE:ICLL)/ Novartis AG (NYSE:NVS; SIX:NOVN…Novartis AG (NYSE:NVS; SIX:NOVN…Novartis AG (NYSE:NVS; SIX:NOVN…
  • Ebb & Flow

    BioCentury on BioBusiness, Finance
    …in 2007; and Paulo Costa, former president and CEO of the U.S. unit of Novartis AG (NYSE:NVS; SIX:NOVN). Then, after market close on Thursday, Amylin released a…
  • 2Q09 milestones

    BioCentury on BioBusiness, Finance
    …NASDAQ:HGSI) ABthrax raxibacumab Anthrax infection Submit BLA 2Q09 Intercell (VSE:ICLL)/CSL (ASX:CSL)/ Novartis (NYSE:NVS; SIX:NOVN) Ixiaro Japanese encephalitis (JE) vaccine Prevent JE infection FDA approval…
  • BioCentury on BioBusiness, Strategy
    …to the triazole derivative from Novartis AG to treat anxiety and…mood disorders, except in Japan. Novartis does have undisclosed buy-back…Germany Novartis AG (NYSE:NVS; SIX:NOVN), Basel…
  • BioCentury on BioBusiness, Analyst Picks & Changes
    …FDA review (see B13). The fusion protein of IFN alpha and albumin is partnered with Novartis (NYSE:NVS; SIX:NOVN). Pegasys is marketed by Roche (SIX:ROG). Bayko thinks the…
  • Ebb & Flow

    BioCentury on BioBusiness, Finance
    …good match for investment partner Novartis (NYSE:NVS; SIX:NOVN). …alongside strategic option deals by Novartis. Thus, the investment company is…have a strategic fund with Novartis and have made a few…
  • BioCentury on BioBusiness, Strategy
    …in 2004, while it has rights to Inovelon from Novartis AG. The new partners hope…NYSE:ELN), Dublin, Ireland Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Sepracor Inc…
  • Ebb & Flow

    BioCentury on BioBusiness, Finance
    …born Clarus Ventures, Novartis Option Fund and MVM Life Science…Clarus and Novartis Option Fund, which were new…Steinmetz and Anja Koenig from Novartis Option Fund joined the company…
  • BioCentury on BioBusiness, Cover Story
    …by Momenta's partner, the Sandoz unit of Novartis AG, is pending at FDA. The techniques Momenta…MNTA), Cambridge, Mass. Novartis AG (NYSE:NVS; SWX:NOVN), Basel, Switzerland sanofi…
  • BioCentury on BioBusiness, Regulation
    …by Momenta's partner, the Sandoz unit of Novartis AG, is pending at FDA. The techniques Momenta…MNTA), Cambridge, Mass. Novartis AG (NYSE:NVS; SWX:NOVN), Basel, Switzerland sanofi…
  • EPS watch

    BioCentury on BioBusiness, Finance
    …of the drug for wet age-related macular degeneration (AMD), as previously reported by partner Novartis (NYSE:NVS; SWX:NOVN), were $30.6M, down 33% from $45.5M in 4Q07…
  • BioCentury on BioBusiness, Product Discovery & Development
    …Now a license deal with Novartis AG will give the biotech…t seem to have worried Novartis, which paid $75 million up…Novartis and Portola will share the…
  • Vertex chronicles

    BioCentury on BioBusiness, Strategy
    …00 - Raises $175M through sale of convertible subordinated notes N. 5/9/00 - Partners with Novartis (NYSE: NVS; SWX:NOVN) to develop small molecules directed at kinase targets O. 9…
  • Ebb & Flow

    BioCentury on BioBusiness, Finance
    …Flow Novartis reloads By…Novartis (NYSE:NVS; SWX:NOVN) caused…NYSE:DNA), the move by Novartis got the rumor mill turning…
  • BioCentury on BioBusiness, Cover Story
    …of Speedel Holding Ltd. by Novartis AG - also might lead CVT…Novartis paid about CHF1 billion ($998…which was already partnered with Novartis, and an early stage pipeline…
  • BioCentury on BioBusiness, Strategy
    …of Speedel Holding Ltd. by Novartis AG - also might lead CVT…Novartis paid about CHF1 billion ($998…which was already partnered with Novartis, and an early stage pipeline…
  • BioCentury on BioBusiness, Strategy
    …Targets lead Novartis to MDx …molecular diagnostics business unit at Novartis AG is the next logical…Mark Fishman to head the Novartis Institutes for BioMedical Research in…
  • BioCentury on BioBusiness, Emerging Company Profiles
    …The newco has already granted Novartis AG an exclusive option to…first deal this month, granting Novartis an exclusive option to license…Md. Novartis AG (NYSE:NVS; SWX:NOVN), Basel…
  • Corporate Profile

    BioCentury on BioBusiness, Emerging Company Profiles
    …collaborators: Tsingua University Corporate partners: Cubist Pharmaceuticals Inc. and Novartis AG Number of employees: 45…Funds raised: Not disclosed Investors: Novartis Option Fund and Bio*One Capital CEO: Steven Tregay…
  • Earnings on deck

    BioCentury on BioBusiness, Finance
    …and big pharma companies are announcing results, including Novartis (NYSE:NVS; SWX:NOVN), which is expected to…55 $0.41 34% Novartis (NYSE:NVS; SWX:NOVN) 1/28 Pre $0…
  • 2009 milestones

    BioCentury on BioBusiness, Cover Story
    …Genentech (NYSE:DNA)/Novartis(NYSE:NVS; SWX:NOVN) …Human Genome (NASDAQ:HGSI)/ Novartis (NYSE:NVS; SWX:NOVN) …Mitsubishi Tanabe (Tokyo:4508; Osaka:4508)/Novartis (NYSE:NVS; SWX:NOVN) Fingolimod…
  • Approval watch

    BioCentury on BioBusiness, Cover Story
    …resectable osteosarcoma EU decision 1Q09 Intercell (VSE:ICLL)/Novartis Ixiaro Japanese Prevent Japanese encephalitis…PDUFA date 4/30/09 Novartis (NYSE:NVS; SWX:NOVN) Afinitor everolimus (RAD001) Advanced kidney…
  • Post-launch report

    BioCentury on BioBusiness, Cover Story
    …U.S./EU $231.1 Novartis (NYSE:NVS; SWX:NOVN) Galvus vildagliptin In combination with…Type II diabetes EU $25 Novartis (NYSE:NVS; SWX:NOVN) Tasigna nilotinib Philadelphia chromosome-positive…
  • Top biotech products

    BioCentury on BioBusiness, Cover Story
    …25% Genentech (NYSE:DNA)/Roche (SWX:ROG)/ Novartis (NYSE:NVS; SWX:NOVN) Lucentis ranibizumab…3 6% Genentech (NYSE:DNA)/Roche (SWX:ROG)/ Novartis (NYSE:NVS; SWX:NOVN) Xolair omalizumab $612…
  • New products to watch

    BioCentury on BioBusiness, Cover Story
    …S. Eisai (Tokyo:4523; Osaka:4523)/Novartis(NYSE:NVS; SWX:NOVN) Banzel…S. Novartis (NYSE:NVS; SWX:NOVN) Extavia…S. Speedel (SWX:SPPN)/ Novartis (NYSE:NVS; SWX:NOVN) Tekturna…
  • 2009 milestones

    BioCentury on BioBusiness, Finance
    …Genentech (NYSE:DNA)/Novartis(NYSE:NVS; SWX:NOVN) …Human Genome (NASDAQ:HGSI)/ Novartis (NYSE:NVS; SWX:NOVN) …Mitsubishi Tanabe (Tokyo:4508; Osaka:4508)/Novartis (NYSE:NVS; SWX:NOVN) Fingolimod…
  • Approval watch

    BioCentury on BioBusiness, Finance
    …resectable osteosarcoma EU decision 1Q09 Intercell (VSE:ICLL)/Novartis Ixiaro Japanese Prevent Japanese encephalitis…PDUFA date 4/30/09 Novartis (NYSE:NVS; SWX:NOVN) Afinitor everolimus (RAD001) Advanced kidney…
  • Post-launch report

    BioCentury on BioBusiness, Finance
    …U.S./EU $231.1 Novartis (NYSE:NVS; SWX:NOVN) Galvus vildagliptin In combination with…Type II diabetes EU $25 Novartis (NYSE:NVS; SWX:NOVN) Tasigna nilotinib Philadelphia chromosome-positive…
  • Top biotech products

    BioCentury on BioBusiness, Finance
    …25% Genentech (NYSE:DNA)/Roche (SWX:ROG)/ Novartis (NYSE:NVS; SWX:NOVN) Lucentis ranibizumab…3 6% Genentech (NYSE:DNA)/Roche (SWX:ROG)/ Novartis (NYSE:NVS; SWX:NOVN) Xolair omalizumab $612…
  • New products to watch

    BioCentury on BioBusiness, Finance
    …S. Eisai (Tokyo:4523; Osaka:4523)/Novartis(NYSE:NVS; SWX:NOVN) Banzel…S. Novartis (NYSE:NVS; SWX:NOVN) Extavia…S. Speedel (SWX:SPPN)/ Novartis (NYSE:NVS; SWX:NOVN) Tekturna…
  • BioCentury on BioBusiness, Emerging Company Profiles
    …Ascent entered into an option agreement with Novartis AG through the Novartis Option Fund under which Ascent will discover…Cambridge, Mass. Novartis AG (NYSE:NVS; SWX:NOVN), Basel, Switzerland…
  • Corporate Profile

    BioCentury on BioBusiness, Emerging Company Profiles
    …University collaborators: Tufts Medical Center Corporate partners: Novartis AG Number of employees: 15 Funds…Funds raised: $19 million Investors: Novartis Option Fund, HealthCare Ventures and TVM Capital CEO: Frederick…
  • BioCentury on BioBusiness, Finance
    …0 0.50 Oral salmon calcitonin in Ph III for osteoarthritis and osteoporosis; partnered with Novartis (NYSE:NVS; SWX:NOVN) Introgen (Pink:INGN) (C) $6.2 $6.3 0.26…
  • BioCentury on BioBusiness, Strategy
    …like the Sandoz International GmbH generics unit of Novartis AG, and Teva Pharmaceuticals Inc. "GlycoFi brings uniformity…Station, N.J. Novartis AG (NYSE:NVS; SWX:NOVN), Basel, Switzerland Teva…
  • BioCentury on BioBusiness, Product Discovery & Development
    …company to target FLT3 inhibition. Cephalon Inc. and Novartis AG have begun Phase III testing of lestaurtinib…CEPH), Frazer, Pa. Novartis AG (NYSE:NVS; SWX:NOVN), Basel, Switzerland…
  • BioCentury on BioBusiness, Regulation
    …containing LABAs: Advair salmeterol/fluticasone and Serevent salmeterol xinafoate from GlaxoSmithKline plc, Foradil formoterol from Novartis AG and Schering-Plough Corp., and Symbicort budesonide/formoterol from AstraZeneca…
  • BioCentury on BioBusiness, Regulation
    …on Coartem artemether/lumefantrine from Novartis AG to address political and…Gabon in 1998, according to Novartis. …panel meeting, FDA agreed with Novartis that Coartem is effective, and…
  • BioCentury on BioBusiness, Regulation
    …Company Product Indication Status Novartis (NYSE:NVS; SWX:NOVN) Coartem artemether (A)/lumefantrine…aminoquinoline Leishmaniasis Ph II Global Alliance for TB Drug Development/Novartis Nitroimidazopyran (PA-824) TB Ph…
  • cSSSI pipeline

    BioCentury on BioBusiness, Cover Story
    …treat cSSSIs, but said it is continuing to develop the compound to treat cSSSI; (C) Novartis (NYSE:NVS; SWX:NOVN) is acquiring Protez (see BioCentury, June 9). Source: BCIQ: BioCentury…
  • cSSSI pipeline

    BioCentury on BioBusiness, Regulation
    …treat cSSSIs, but said it is continuing to develop the compound to treat cSSSI; (C) Novartis (NYSE:NVS; SWX:NOVN) is acquiring Protez (see BioCentury, June 9). Source: BCIQ: BioCentury…
  • End of life candidates

    BioCentury on BioBusiness, Regulation
    …Advanced gastric cancer 6/11/09 Sprycel dasatinib and Tasigna nilotinib Bristol-Myers and Novartis (NYSE:NVS; SWX:NOVN), respectively Chronic myelogenous leukemia (CML) 10/14/09 Xeloda capecitabine Roche…
  • BioCentury on BioBusiness, Product Discovery & Development
    …resistant to Gleevec imatinib from Novartis AG regained sensitivity to the…lead being fingolimod (FTY720) from Novartis, which has rights to the…Japan Novartis AG (NYSE:NVS; SWX:NOVN), Basel…
  • BioCentury on BioBusiness, Strategy
    …were used to screen a compound library from Novartis AG. That work yielded several hits that would…Venture, Geneva, Switzerland Novartis AG (NYSE:NVS; SWX:NOVN), Basel, Switzerland Palumed…
  • EPS watch

    BioCentury on BioBusiness, Finance
    …of the drug for wet age-related macular degeneration (AMD), as previously reported by partner Novartis (NYSE:NVS; SWX:NOVN), were $34.1M, down 30% from $48.7M in 3Q07…
  • BioCentury on BioBusiness, Regulation
    …Taylor. Novartis AG, which is potentially the first…be eligible for a voucher, Novartis Spokesperson Peter Shelby said that…Shelby said Novartis has not had any discussions…
  • BioCentury on BioBusiness, Emerging Company Profiles
    …cancer (NSCLC) and metastatic breast cancer. Genentech and Novartis AG market Lucentis to treat wet age-related…San Francisco, Calif. Novartis AG (NYSE:NVS; SWX:NOVN), Basel, Switzerland PhiloGene…
  • Ebb & Flow

    BioCentury on BioBusiness, Finance
    …its pulmonary delivery business to Novartis (NYSE:NVS; SWX:NOVN) for…The company expects the Novartis deal to shrink its annual…Novartis gets Nektar's dry powder…
  • Earnings on deck

    BioCentury on BioBusiness, Finance
    …Company Date Pre/post mkt 3Q08 EPS est 3Q07 EPS Expected chg Novartis (NYSE:NVS; SWX:NOVN) 10/20 Pre $0.95 $0.68 40% Actelion (SWX:ATLN) 10…
  • BioCentury on BioBusiness, Product Discovery & Development
    …Avastin and Lucentis are marketed elsewhere by Roche and Novartis AG, respectively. COMPANIES AND INSTITUTIONS MENTIONED…Institute (NEI), Bethesda, Md. Novartis AG (NYSE:NVS; SWX:NOVN), Basel, Switzerland Roche (SWX…
  • BioCentury on BioBusiness, Cover Story
    …since January 2007, led by Novartis AG's $10.4 billion…global head of ophthalmology at Novartis Institutes for Biomedical Research. "One…Novartis, which has been in the…
  • BioCentury on BioBusiness, Product Discovery & Development
    …since January 2007, led by Novartis AG's $10.4 billion…global head of ophthalmology at Novartis Institutes for Biomedical Research. "One…Novartis, which has been in the…
  • Ophthalmic deals

    BioCentury on BioBusiness, Cover Story
    …ophthalmic indications Jul 08 Alcon (NYSE:ACL)/ Novartis (NYSE:NVS; SWX:NOVN) $10.4B cash Novartis…NOVN) $10.4B cash Novartis acquires a 25% stake in Alcon from Nestle (SWX…
  • Ophthalmic deals

    BioCentury on BioBusiness, Product Discovery & Development
    …ophthalmic indications Jul 08 Alcon (NYSE:ACL)/ Novartis (NYSE:NVS; SWX:NOVN) $10.4B cash Novartis…NOVN) $10.4B cash Novartis acquires a 25% stake in Alcon from Nestle (SWX…
  • BioCentury on BioBusiness, Regulation
    …inhaled formulation for CF patients, TOBI tobramycin from Novartis AG, which was approved about 10 years ago…Foster City, Calif. Novartis AG (NYSE:NVS; SWX:NOVN), Basel, Switzerland Ohio…
  • BioCentury on BioBusiness, Product Discovery & Development
    …to the newly launched bisphosphonate Reclast zoledronic acid from Novartis AG (NYSE:NVS; SWX:NOVN). Reclast was approved for…zoledronic acid Company Amgen Merck Novartis Study [n] 3-year Ph…
  • BioCentury on BioBusiness, Regulation
    …LAR octreotide acetate depot Novartis (NYSE:NVS; SWX:NOVN) Ileus Seroquel quetiapine AstraZeneca…Skin melanomas Tyzeka telbivudine Idenix (NASDAQ:IDIX)/Novartis (NYSE:NVS; SWX:NOVN) Peripheral neuropathy…
  • BioCentury on BioBusiness, Strategy
    …galantamine from Shire plc, and Exelon rivastigmine from Novartis AG. The only marketed NMDA receptor antagonist is…NTII), Emeryville, Calif. Novartis AG (NYSE:NVS; SWX:NOVN), Basel, Switzerland Pfizer…
  • BioCentury on BioBusiness, Cover Story
    …market leader Lucentis ranibizumab from Genentech Inc. and Novartis AG. But doctors are already dosing Lucentis less…AMD patients. Genentech and Novartis also have followed the lead of current…
  • BioCentury on BioBusiness, Product Discovery & Development
    …market leader Lucentis ranibizumab from Genentech Inc. and Novartis AG. But doctors are already dosing Lucentis less…AMD patients. Genentech and Novartis also have followed the lead of current…
  • BioCentury on BioBusiness, Regulation
    Regulation Deconstructing iloperidone By Steve Usdin & Erin McCallister Senior Writers Iloperidone efficacy Discontinuations FDA has added schizophrenia to the list of diseases and conditions for which the …
  • BioCentury on BioBusiness, Product Discovery & Development
    …head-to-head with Reclast zoledronic acid from Novartis AG. “Denosumab would probably not compete directly against…Station, N.J. Novartis AG (NYSE:NVS; SWX:NOVN), Basel, Switzerland Oregon…
  • Genentech pipeline

    BioCentury on BioBusiness, Cover Story
    …III [adjuvant HER2-pos breast cancer] Lucentis ranibizumab [Novartis] VEGF Ph III [diabetic macular edema…venous access device occlusion, catheter clearance] Xolair omalizumab [Novartis] IgE Ph III [pediatric asthma] Raptiva…
  • EPS Watch

    BioCentury on BioBusiness, Finance
    …2Q07. Lucentis is partnered with Novartis (NYSE:NVS; SWX:NOVN). U…Novartis (NYSE:NVS; SWX:NOVN) $…internationally, although U.S. sales fell. Novartis said EPS was helped by a…
  • BioCentury on BioBusiness, Politics and Policy
    Politics & Policy Global health vouchers: Round 2 By Aaron Bouchie Senior Writer Voucher eligible When the FDA Amendments Act of 2007 (FDAAA) became law last September, it included a largely unnoticed mechanism …
  • BioCentury on BioBusiness, Strategy
    Novartis AG may not have surprised…had sold their holdings to Novartis, increasing the pharma company’s…Novartis paid CHF130 ($125.90) a…
  • 2H milestones

    BioCentury on BioBusiness, Finance
    …Genentech (NYSE:DNA)/ Novartis (NYSE:NVS; SWX:NOVN) …2H08 Genentech (NYSE:DNA)/ Novartis (NYSE:NVS; SWX:NOVN) Xolair…2H08 Human Genome Sciences (NASDAQ:HGSI/ Novartis (NYSE:NVS; SWX:NOVN) Albuferon…
  • 2Q approvals

    BioCentury on BioBusiness, Finance
    …gout Novartis (NYSE:NVS; SWX:NOVN) EC…of multiple sclerosis (MS). Extavia is Novartis’ branded version of Betaseron (Betaferon - EU…disease (AD) Novartis (NYSE:NVS; SWX:NOVN) Withdraws an…
  • BioCentury on BioBusiness, Product Discovery & Development
    …of synthetic salmon calcitonin hormone is partnered with Novartis AG and its partner Nordic Bioscience Diagnostics A…S, Herlev, Denmark Novartis AG (NYSE:NVS; SWX:NOVN), Basel, Switzerland Novo…
  • Corporate Profile

    BioCentury on BioBusiness, Emerging Company Profiles
    …2005 by Stavros Therianos, Jacques Essinger, Jean-Pierre Rosat, Novartis Venture Fund University collaborators: Swiss Institute…raised: CHF700,000 ($670,000) Investors: Novartis Venture Fund Patents: 2 issued covering Colox…
  • BioCentury on BioBusiness, Strategy
    …the U.S. by Genentech and elsewhere by Novartis AG for age-related macular degeneration (AMD). Other…San Francisco, Calif. Novartis AG (NYSE:NVS; SWX:NOVN), Basel, Switzerland Regeneron…
  • BioCentury on BioBusiness, Strategy
    …have a similar arrangement with Novartis on a cyclin-dependent kinase…AT13387, are still unpartnered, while Novartis AG has an option to…Earlier this year, Novartis exercised an option to extend…
  • BioCentury on BioBusiness, Strategy
    …own. Novartis AG had plans to vie for…S. before 2010. In the meantime, Novartis has begun marketing Galvus in Europe…J. Novartis AG (NYSE:NVS; SWX:NOVN), Basel…
  • BioCentury on BioBusiness, Strategy
    …contributed to the development of Novartis AG's Gleevec imatinib to…former president and CEO of Novartis' Novartis Pharma K.K. unit, also…Novartis AG (NYSE:NVS; SWX:NOVN…
  • BioCentury on BioBusiness, Cover Story
    Strategy String of pearls By Aaron Bouchie Senior Writer Kosan Chronicles In early 2007, Bristol-Myers Squibb Co. concluded it needed to give itself a dose of strong medicine if it were to survive and prosper. …
  • BioCentury on BioBusiness, Strategy
    Strategy String of pearls By Aaron Bouchie Senior Writer Kosan Chronicles In early 2007, Bristol-Myers Squibb Co. concluded it needed to give itself a dose of strong medicine if it were to survive and prosper. …
  • BioCentury on BioBusiness, Product Discovery & Development
    …Laboratories Inc., and Zelnorm tegaserod from Novartis AG. Results…AG. Results of Novartis' B251 Phase II dose-ranging study…Darmstadt, Germany Novartis AG (NYSE:NVS; SWX:NOVN), Basel, Switzerland…
  • Intercell's pipeline

    BioCentury on BioBusiness, Cover Story
    …prophylactic) Registration (A) Biological E; CSL (ASX:CSL); Novartis (NYSE:NVS; SWX:NOVN) Travelers' diarrhea vaccine…Ph II 2009) Novartis Immunostimulant (IS) adjuvant…I/II 2008) Novartis Tuberculosis vaccine (prophylactic…
  • BioCentury on BioBusiness, Product Discovery & Development
    …of Lotrel amlodipine/benazepril from Novartis AG as an example that…Novartis also markets Exforge, a combination…valsartan, an ARB marketed by Novartis, but the company halted a…
  • Intercell's pipeline

    BioCentury on BioBusiness, Strategy
    …prophylactic) Registration (A) Biological E; CSL (ASX:CSL); Novartis (NYSE:NVS; SWX:NOVN) Travelers' diarrhea vaccine…Ph II 2009) Novartis Immunostimulant (IS) adjuvant…I/II 2008) Novartis Tuberculosis vaccine (prophylactic…
  • BioCentury on BioBusiness, Product Discovery & Development
    Novartis AG says its Menveo quadrivalent…Joerg Reinhart, CEO of the Novartis Vaccines unit. "The difference is…In Novartis' head-to-head study, Menveo…
  • EPS watch

    BioCentury on BioBusiness, Finance
    …Flow EPS watch With at least 23 biotech and pharma companies reporting earnings last week, Novartis (NYSE:NVS; SWX:NOVN) gained the most in market value, adding $6B on the…
  • Corporate Profile

    BioCentury on BioBusiness, Emerging Company Profiles
    …Center/Harvard Medical School Corporate partners: Novartis AG Number of employees: 25…Ventures, New England Partners/Nexus Medical Partners, Pappas Ventures and Novartis Option Fund CEO: Peter Parker Patents: None…
  • BioCentury on BioBusiness, Emerging Company Profiles
    …will study eight RNAi targets supplied by partner Novartis AG, screen them in vitro, and try the…School, Boston, Mass. Novartis AG (NYSE:NVS; SWX:NOVN), Basel, Switzerland…
  • Earnings on deck

    BioCentury on BioBusiness, Finance
    …age-related macular degeneration (AMD) and partnered with Novartis (NYSE:NVS; SWX:NOVN), are declining due primarily…86 $0.84 2% Novartis (NYSE:NVS; SWX:NOVN) 4/21 Pre $0…
  • BioCentury on BioBusiness, Regulation
    Novartis AG got none of what…that the evidence presented by Novartis did not support the cost…the economic model provided by Novartis. …
  • BioCentury on BioBusiness, Product Discovery & Development
    …to build on a deal with Novartis AG for another molecule, ASA404 (formerly…Under the Novartis deal for '404, we have…Novartis licensed ASA404 in 2007. The…
  • Nomura's investments

    BioCentury on BioBusiness, Finance
    …Equity; Hanseatic Corp.; MPM Capital; Novartis BioVenture Fund; Swan Private Equity…Fund; HBM BioVentures; Lombard Odier; Novartis; POD Holding; Wheatley Partners $…Technology Growth Capital; Lombard Odier; Novartis BioVenture Fund …
  • Ebb & Flow Focus

    BioCentury on BioBusiness, Finance
    …IPO window was closed and M&A seemed unlikely, Idenix sold a 51% stake to Novartis for $255 million in cash plus up to $357 million in milestones. That deal…
  • BioCentury on BioBusiness, Product Discovery & Development
    …The Novartis Institute for Tropical Diseases, one…three research institutes funded by Novartis AG, is developing novel treatments…for multi-drug resistant TB. Novartis is collaborating with the TB…
  • BioCentury on BioBusiness, Strategy
    …Ertel. Zometa zoledronic acid, an intravenous bisphosphonate from Novartis AG, which works by preventing bone resorption but…LLY), Indianapolis, Ind. Novartis AG (NYSE:NVS; SWX:NOVN), Basel, Switzerland…
  • BioCentury on BioBusiness, Strategy
    …LSE:GSK; NYSE:GSK) and Zelnorm tegaserod from Novartis (NYSE:NVS; SWX:NOVN), which target serotonin (5…disease Ph II Cerimon/Novartis (NYSE:NVS; SWX:NOVN) Basiliximab Chimeric antibody…
  • BioCentury on BioBusiness, Strategy
    …relationship between MorphoSys AG and Novartis AG make Dyax one of…10-year deal essentially giving Novartis exclusive access to the biotech…Germany Novartis AG (NYSE:NVS; SWX:NOVN), Basel…
  • BioCentury on BioBusiness, Politics and Policy
    …tyrosine kinase inhibitor marketed by Novartis AG to treat chronic myelogenous…Designs at Chennai rejected a Novartis patent covering Gleevec on the…India dismissed a petition from Novartis seeking to have provisions of…
  • BioCentury on BioBusiness, Product Discovery & Development
    …group." HGS and partner Novartis AG haven't given up on…spring. HGS and Novartis expect to begin submitting global marketing…Md. Novartis AG (NYSE:NVS; SWX:NOVN), Basel…
  • BioCentury on BioBusiness, Strategy
    …the high-dose arms. Albuferon is partnered with Novartis AG (see "Lower Dose Will Have to Work…HGSI), Rockville, Md. Novartis AG (NYSE:NVS; SWX:NOVN), Basel, Switzerland Teva…
  • Differences of opinion

    BioCentury on BioBusiness, Cover Story
    …18 Galvus vildagliptin Novartis (NYSE:NVS; SWX:NOVN) 2007: FDA approvable…including a clinical study in patients with renal impairment. Novartis announced last week that it would put its U…
  • Differences of opinion

    BioCentury on BioBusiness, Regulation
    …18 Galvus vildagliptin Novartis (NYSE:NVS; SWX:NOVN) 2007: FDA approvable…including a clinical study in patients with renal impairment. Novartis announced last week that it would put its U…
  • New products to watch

    BioCentury on BioBusiness, Cover Story
    …Eisai (Tokyo:4523; Osaka:4523)/ Novartis (NYSE:NVS; SWX:NOVN) …Genentech (NYSE:DNA)/Novartis (NYSE:NVS; SWX:NOVN) …Idenix (NASDAQ:IDIX)/Novartis (NYSE:NVS; SWX:NOVN) …
  • Post-launch report

    BioCentury on BioBusiness, Cover Story
    …S. $78.3 Genentech (NYSE:DNA)/ Novartis (NYSE:NVS; SWX:NOVN) Lucentis ranibizumab Wet…S. $124.4 SkyePharma (LSE:SKP; NASDAQ:SKYE)/Novartis (NYSE:NVS; SWX:NOVN) Foradil Certihaler formoterol…
  • Approval watch

    BioCentury on BioBusiness, Cover Story
    …ED) FDA action 3Q08 Novartis (NYSE:NVS; SWX:NOVN) Aflunov Prevent influenza virus…action 3/7/08 Speedel (SWX:SPPN)/Novartis (NYSE:NVS; SWX:NOVN) Tekturna HCT (aliskiren/ hydrochlorothiazide…
  • Late stage milestones

    BioCentury on BioBusiness, Cover Story
    …IDEC-Y2B8) Advanced stage follicular lymphoma Submit sBLA 2008 Cell Therap (NASDAQ:CTIC; NMerc:CTIC)/Novartis (NYSE:NVS; SWX:NOVN) Xyotax paclitaxel poliglumex NSCLC Submit MAA 1Q08 Cellegy (CLGY)/Prostrakan…
  • New products to watch

    BioCentury on BioBusiness, Finance
    …Eisai (Tokyo:4523; Osaka:4523)/ Novartis (NYSE:NVS; SWX:NOVN) …Genentech (NYSE:DNA)/Novartis (NYSE:NVS; SWX:NOVN) …Idenix (NASDAQ:IDIX)/Novartis (NYSE:NVS; SWX:NOVN) …
  • BioCentury on BioBusiness, Finance
    …company and partner Sandoz, the generics unit of Novartis AG, received a not approvable letter for an…MNTA), Cambridge, Mass. Novartis AG (NYSE:NVS; SWX:NOVN), Basel, Switzerland Pharmion…
  • Post-launch report

    BioCentury on BioBusiness, Finance
    …S. $78.3 Genentech (NYSE:DNA)/ Novartis (NYSE:NVS; SWX:NOVN) Lucentis ranibizumab Wet…S. $124.4 SkyePharma (LSE:SKP; NASDAQ:SKYE)/Novartis (NYSE:NVS; SWX:NOVN) Foradil Certihaler formoterol…
  • Approval watch

    BioCentury on BioBusiness, Finance
    …ED) FDA action 3Q08 Novartis (NYSE:NVS; SWX:NOVN) Aflunov Prevent influenza virus…action 3/7/08 Speedel (SWX:SPPN)/Novartis (NYSE:NVS; SWX:NOVN) Tekturna HCT (aliskiren/ hydrochlorothiazide…
  • Late stage milestones

    BioCentury on BioBusiness, Finance
    …IDEC-Y2B8) Advanced stage follicular lymphoma Submit sBLA 2008 Cell Therap (NASDAQ:CTIC; NMerc:CTIC)/Novartis (NYSE:NVS; SWX:NOVN) Xyotax paclitaxel poliglumex NSCLC Submit MAA 1Q08 Cellegy (CLGY)/Prostrakan…
  • BioCentury on BioBusiness, Cover Story
    …One deal, many MOR antibodies Novartis' antibody deals Novartis (NVS; SWX:NOVN) is…MOR antibodies Novartis' antibody deals Novartis (NVS; SWX:NOVN) is looking to establish biologics as a…
  • BioCentury on BioBusiness, Strategy
    …One deal, many MOR antibodies Novartis' antibody deals Novartis (NVS; SWX:NOVN) is…MOR antibodies Novartis' antibody deals Novartis (NVS; SWX:NOVN) is looking to establish biologics as a…
  • BioCentury on BioBusiness, Cover Story
    …Turning the corner MorphoSys partnerships Novartis' antibody deals MorphoSys chronicles Big…new 10-year deal with Novartis AG to be transformational, providing…for its platform technologies. For Novartis, the deal will provide a…
  • BioCentury on BioBusiness, Strategy
    …Turning the corner MorphoSys partnerships Novartis' antibody deals MorphoSys chronicles Big…new 10-year deal with Novartis AG to be transformational, providing…for its platform technologies. For Novartis, the deal will provide a…
  • Big antibody deals

    BioCentury on BioBusiness, Cover Story
    …month's deal between MorphoSys (FSE:MOR) and Novartis (NVS; SWX:NOVN). Topping the list is the…Suite Deal," A8). MorphoSys (FSE:MOR) Novartis (NVS; SWX:NOVN) 2007 $1,000…
  • MorphoSys partnerships

    BioCentury on BioBusiness, Cover Story
    …partnerships with 13 companies. With its blockbuster deal with Novartis (NVS; SWX:NOVN) in hand, MOR said it does…antibody generation system Novartis (NVS; SWX:NOVN) 2007 10 yrs…
  • Big antibody deals

    BioCentury on BioBusiness, Strategy
    …month's deal between MorphoSys (FSE:MOR) and Novartis (NVS; SWX:NOVN). Topping the list is the…Suite Deal," A8). MorphoSys (FSE:MOR) Novartis (NVS; SWX:NOVN) 2007 $1,000…
  • MorphoSys partnerships

    BioCentury on BioBusiness, Strategy
    …partnerships with 13 companies. With its blockbuster deal with Novartis (NVS; SWX:NOVN) in hand, MOR said it does…antibody generation system Novartis (NVS; SWX:NOVN) 2007 10 yrs…
  • 3Q approvals

    BioCentury on BioBusiness, Finance
    …GBM) Novartis (NVS; SWX:NOVN) FDA…Novartis (NVS; SWX:NOVN) …Novartis (NVS; SWX:NOVN) …
  • 4Q milestones

    BioCentury on BioBusiness, Finance
    …Depression PDUFA date Nov. 2 Genentech (DNA)/Novartis (NVS; SWX:NOVN) Lucentis ranibizumab Age-related macular…spray Insomnia Submit NDA 4Q07 Novartis (NVS; SWX:NOVN) Tasigna nilotinib (AMN107) Chronic myelogenous…
  • Big pharma beat down

    BioCentury on BioBusiness, Finance
    …Only three of the 13 - Merck, Novartis and Roche - were rewarded by investors…turning attention away from Vioxx. Novartis reported a 16% increase in…2Q06 Novartis (NVS; SWX:NOVN) $116…
  • Novartis' options

    BioCentury on BioBusiness, Cover Story
    …Story: Strategy: Degrees of freedom Novartis' options Novartis (NVS; SWX:NOVN) has…Strategy: Degrees of freedom Novartis' options Novartis (NVS; SWX:NOVN) has an option to develop, manufacture and commercialize…
  • Novartis' options

    BioCentury on BioBusiness, Strategy
    …Story: Strategy: Degrees of freedom Novartis' options Novartis (NVS; SWX:NOVN) has…Strategy: Degrees of freedom Novartis' options Novartis (NVS; SWX:NOVN) has an option to develop, manufacture and commercialize…
  • BioCentury on BioBusiness, Cover Story
    …Intercell chronicles Novartis' options Big platform deals …and Roche, the 2003 deal Novartis AG did with Idenix Pharmaceuticals…with Theravance Inc. Last week, Novartis and Intercell AG did another…
  • Intercell chronicles

    BioCentury on BioBusiness, Cover Story
    …2005. Last week's deal with Novartis Vaccines & Diagnostics makes Novartis (NVS; SWX:NOVN) the company's…trial E. 6/13/06 - Novartis (NVS; SWX:NOVN) receives rights to…
  • BioCentury on BioBusiness, Strategy
    …Intercell chronicles Novartis' options Big platform deals …and Roche, the 2003 deal Novartis AG did with Idenix Pharmaceuticals…with Theravance Inc. Last week, Novartis and Intercell AG did another…
  • Intercell chronicles

    BioCentury on BioBusiness, Strategy
    …2005. Last week's deal with Novartis Vaccines & Diagnostics makes Novartis (NVS; SWX:NOVN) the company's…trial E. 6/13/06 - Novartis (NVS; SWX:NOVN) receives rights to…
  • Big platform deals

    BioCentury on BioBusiness, Cover Story
    …partnership; $M Idenix Theravance Intercell Pharma partner Novartis GlaxoSmithKline Novartis Focus Antivirals Respiratory and other…Idenix Theravance Intercell Pharma partner Novartis GlaxoSmithKline Novartis Focus Antivirals Respiratory and other Vaccines Year…
  • Big platform deals

    BioCentury on BioBusiness, Strategy
    …partnership; $M Idenix Theravance Intercell Pharma partner Novartis GlaxoSmithKline Novartis Focus Antivirals Respiratory and other…Idenix Theravance Intercell Pharma partner Novartis GlaxoSmithKline Novartis Focus Antivirals Respiratory and other Vaccines Year…
  • 2H milestones

    BioCentury on BioBusiness, Finance
    …Aug. 30 Intercell (VSE:ICLL)/Novartis (NVS; SWX:NOVN)/Biological E. IC51 Japanese…NDA 2H07 Novartis (NVS; SWX:NOVN) Tasigna nilotinib…action 2H07 Novartis (NVS; SWX:NOVN) Galvus Diabetes…
  • 2Q approvals

    BioCentury on BioBusiness, Finance
    …not responded to trastuzumab therapy Idenix (IDIX)/Novartis (NVS; SWX:NOVN) EC approves Sebivo telbivudine to…release tablets to treat schizophrenia Novartis (NVS; SWX:NOVN) EC approves Optaflu cell culture…
  • BioCentury on BioBusiness, Strategy
    …Edelson Senior Writer Tekturna aliskiren from Novartis AG and Speedel AG already faces an uphill…in the hierarchy." SPPN and partner Novartis (NVS; SWX:NOVN, Basel, Switzerland) don't plan…
  • Ebb & Flow

    BioCentury on BioBusiness, Finance
    Novartis opts in …Novartis has launched a new venture…venture fund, the $200 million Novartis Option Fund, which will give…
  • Comparing multiples

    BioCentury on BioBusiness, Cover Story
    …exercised options; (B) 2005 revenues used for Chiron; Novartis paid about $5.2B for the 56% it…15.6 12.2 Chiron (acq. by Novartis) (B) $1.9 $9.2…
  • BioCentury on BioBusiness, Product Discovery & Development
    …Christopher Maggos Senior Writer Cytos Biotechnology AG says Novartis AG in-licensed its CYT002-NicQb nicotine vaccine - which…optimal administration regimen. Novartis (NVS; SWX:NOVN, Basel, Switzerland) obtained exclusive, worldwide…
  • Comparing multiples

    BioCentury on BioBusiness, Strategy
    …exercised options; (B) 2005 revenues used for Chiron; Novartis paid about $5.2B for the 56% it…15.6 12.2 Chiron (acq. by Novartis) (B) $1.9 $9.2…
  • BioCentury on BioBusiness, Strategy
    …AS1404, which Roche passed on last year, as Novartis AG picked up a license in exchange for…non-oncology indication. Novartis (NVS; SWX:NOVN, Basel, Switzerland) also will fund…
  • 1Q approvals

    BioCentury on BioBusiness, Finance
    …Eisai (Tokyo:4523; Osaka:4523)/Novartis (NVS; SWX:NOVN) …Genentech (DNA)/Novartis (NVS; SWX:NOVN) …Idenix (IDIX)/Novartis (NVS; SWX:NOVN) …
  • BioCentury on BioBusiness, Analyst Picks & Changes
    …Albuferon for HCV that is partnered with Novartis (NVS; SWX:NOVN), and LymphoStat-B for…value of last year's deal with Novartis (NVS; SWX:NOVN) to develop and commercialize…
  • BioCentury on BioBusiness, Product Discovery & Development
    …Januvia sitagliptin, which was approved in October. But Novartis AG elected not to run a trial as…way Januvia is. Novartis (NVS; SWX:NOVN, Basel, Switzerland) is unsure how…
  • Development deficit

    BioCentury on BioBusiness, Cover Story
    …methylphenidate Mkt Novartis/Celgene Focalin Dexmethylphenidate…Mkt Novartis/Celgene Ritalin…Methylphenidate Mkt Novartis/Celgene Ritalin SR…
  • Development deficit

    BioCentury on BioBusiness, Strategy
    …methylphenidate Mkt Novartis/Celgene Focalin Dexmethylphenidate…Mkt Novartis/Celgene Ritalin…Methylphenidate Mkt Novartis/Celgene Ritalin SR…
  • BioCentury on BioBusiness, Politics and Policy
    …No (Feb 02) Betaseron Bayer Schering/ Novartis MS Yes Yes Yes…ankylosing spondylitis) Femara (PR) Novartis Hormone receptor- positive early…NA Gleevec (PR, O) Novartis Chronic myeloid leukemia (CML…
  • M&A comps

    BioCentury on BioBusiness, Cover Story
    …in October 2006; (B) Premium based on price before Novartis’ bid in October 2005; Purchase price in $B Acquisition…20% $13.2 Chiron (B) Novartis 11% $5.2 [for remaining…
  • M&A comps

    BioCentury on BioBusiness, Strategy
    …in October 2006; (B) Premium based on price before Novartis’ bid in October 2005; Purchase price in $B Acquisition…20% $13.2 Chiron (B) Novartis 11% $5.2 [for remaining…
  • BioCentury on BioBusiness, Analyst Picks & Changes
    …compound ANA975. McCarthy said ANDS and partner Novartis (NVS; SWX:NOVN) could restart the trial…with Merck (MRK) for vaccines and with Novartis (NVS; SWX:NOVN) for respiratory diseases. Internally…
  • BioCentury on BioBusiness, Cover Story
    …AMD; DME Ph II compl (B) Genentech/Novartis Lucentis ranibizumab Humanized monoclonal antibody fragment…neurotrophic factor (CNTF) Dry AMD Ph II Novartis PTK787 Oral VEGF inhibitor Wet AMD Ph…
  • BioCentury on BioBusiness, Product Discovery & Development
    …AMD; DME Ph II compl (B) Genentech/Novartis Lucentis ranibizumab Humanized monoclonal antibody fragment…neurotrophic factor (CNTF) Dry AMD Ph II Novartis PTK787 Oral VEGF inhibitor Wet AMD Ph…
  • Late stage milestones

    BioCentury on BioBusiness, Cover Story
    …1H07 Cell Therap (CTIC; NMerc:CTIC)/Novartis (NVS; SWX:NOVN) Xyotax…Genentech (DNA)/Novartis (NVS; SWX:NOVN) …Novartis (NVS; SWX:NOVN) …
  • Late stage milestones

    BioCentury on BioBusiness, Finance
    …1H07 Cell Therap (CTIC; NMerc:CTIC)/Novartis (NVS; SWX:NOVN) Xyotax…Genentech (DNA)/Novartis (NVS; SWX:NOVN) …Novartis (NVS; SWX:NOVN) …
  • Approval watch

    BioCentury on BioBusiness, Cover Story
    …action March Novartis (NVS; SWX:NOVN) Galvus vildagliptin…date Feb Novartis (NVS; SWX:NOVN) Optaflu vaccine…5/21/07 Speedel (SWX:SPPN)/ Novartis (NVS; SWX:NOVN) Tekturna aliskiren Hypertension…
  • Approval watch

    BioCentury on BioBusiness, Finance
    …action March Novartis (NVS; SWX:NOVN) Galvus vildagliptin…date Feb Novartis (NVS; SWX:NOVN) Optaflu vaccine…5/21/07 Speedel (SWX:SPPN)/ Novartis (NVS; SWX:NOVN) Tekturna aliskiren Hypertension…
  • New products to watch

    BioCentury on BioBusiness, Cover Story
    …S. Genentech (DNA)/Novartis (NVS; SWX:NOVN) Lucentis…thromboembolism EU Idenix (IDIX) Novartis (NVS; SWX:NOVN) Tyzeka telbivudine…U.S.) SkyePharma (LSE:SKP; SKYE)/Novartis (NVS; SWX:NOVN) Foradil Certihaler…
  • New products to watch

    BioCentury on BioBusiness, Finance
    …S. Genentech (DNA)/Novartis (NVS; SWX:NOVN) Lucentis…thromboembolism EU Idenix (IDIX) Novartis (NVS; SWX:NOVN) Tyzeka telbivudine…U.S.) SkyePharma (LSE:SKP; SKYE)/Novartis (NVS; SWX:NOVN) Foradil Certihaler…
  • BioCentury on BioBusiness, Strategy
    …is marketed in the U.S. by Novartis AG (NVS; SWX:NOVN, Basel, Switzerland) for…more pronounced for Resolor than with the Novartis product," Reyn said. "The strength of the…
  • 4Q approvals

    BioCentury on BioBusiness, Finance
    …menopause Gen-Probe (GPRO)/ Novartis (NVS; SWX:NOVN) FDA…hypertension Idenix (IDIX)/ Novartis (NVS; SWX:NOVN) FDA…seborrheic dermatitis SkyePharma (LSE:SKP; SKYE)/ Novartis (NVS; SWX:NOVN) FDA approves…
  • BioCentury on BioBusiness, Product Discovery & Development
    …In 2002, Novartis AG dropped development of schizophrenia…and dopamine receptor antagonist to Novartis (NVS; SWX:NOVN, Basel, Switzerland…overestimated at the time. "When Novartis made the decision, prolonged QTc…
  • BioCentury on BioBusiness, Strategy
    …growth rates, Pfizer Inc. and Novartis AG last week devoted considerable…As for Novartis (NVS; SWX:NOVN, Basel, Switzerland…Mark Fishman, president of the Novartis Institutes for Biomedical Research, said…
  • BioCentury on BioBusiness, Analyst Picks & Changes
    …and albumin, is partnered with Novartis (NVS; SWX:NOVN) and is…Both compounds are partnered with Novartis (NVS; SWX:NOVN). …after the company said partner Novartis (NVS; SWX:NOVN) plans to…
  • Future production

    BioCentury on BioBusiness, Strategy
    …goal Future production Both Novartis and Pfizer expect more from their development efforts…not apples-to-apples. From 2007 to 2009, Novartis (NVS; SWX:NOVN) projects its regulatory filings for…
  • BioCentury on BioBusiness, Tools & Techniques
    …siRNA candidates, while pharma companies such as Novartis AG (NVS; SWX:NOVN, Basel, Switzerland) and…said Azab. When Intradigm spun out from Novartis in 2000, "it was perceived as more…
  • BioCentury on BioBusiness, Strategy
    …the marketing arrangement for Xolair that previously involved Novartis AG as well as Tanox, and DNA expects…919 million. DNA, TNOX and Novartis (NVS; SWX:NOVN, Basel, Switzerland) have been…
  • BioCentury on BioBusiness, Strategy
    …than molecules such as FTY 720 from Novartis and Tysabri from Biogen Idec, which target…by existing investors Lombard Odier Darier Hentsch; Novartis Venture Fund; and Aravis Venture, as well…
  • HCV immunotherapeutics

    BioCentury on BioBusiness, Cover Story
    …101 HCV therapeutic vaccine Ph IIb Human Genome/ Novartis Albuferon Fusion protein of IFN alpha…and ribavirin Ph I/II compl Anadys/Novartis ANA975 Oral prodrug of isatoribine, a…
  • HCV immunotherapeutics

    BioCentury on BioBusiness, Regulation
    …101 HCV therapeutic vaccine Ph IIb Human Genome/ Novartis Albuferon Fusion protein of IFN alpha…and ribavirin Ph I/II compl Anadys/Novartis ANA975 Oral prodrug of isatoribine, a…
  • RNAi hedging

    BioCentury on BioBusiness, Strategy
    …Protiva (2005) (B) Infectious Biogen Idec (2006) Novartis (2006) Neurology Medtronic (2005) Targeted…Broad and/or undisclosed Benitec (2005) Novartis (2005) Isis (2004) Merck (2003)…
  • BioCentury on BioBusiness, Product Discovery & Development
    …FDA on Galvus vildagliptin, a DPP-4 inhibitor from Novartis AG. Glucagon-like peptide-1…one replacement," he said. Novartis (NVS; SWX:NOVN, Basel, Switzerland) expects an FDA decision…
  • 4Q milestones

    BioCentury on BioBusiness, Finance
    …NDA YE06 Idenix (IDIX)/ Novartis (NVS; SWX:NOVN) Telbivudine HBV…YE06 Intercell (VSE:ICLL)/ Novartis (NVS; SWX:NOVN) Japanese…action November Novartis (NVS; SWX:NOVN)/ Speedel (SWX:SPPN) Rasilez…
  • BioCentury on BioBusiness, Product Discovery & Development
    …III trials. But last week, Novartis AG took out a cheap…Novartis (SWX:NVS; NOVN, Basel, Switzerland…at the pharma company's Novartis Oncology subsidiary. "Novartis has some early work going…
  • BioCentury on BioBusiness, Product Discovery & Development
    …Vectura Group plc and partner Novartis AG recently released positive Phase…safety and tolerability options that Novartis might want to explore." …revenues. Novartis (NVS; SWX:NOVN, Basel, Switzerland) entered…
  • 2Q approvals

    BioCentury on BioBusiness, Finance
    …following surgery and standard chemotherapy Genentech (DNA)/Novartis (NVS; SWX:NOVN) FDA approves Lucentis ranibizumab for…to treat myelodysplastic syndromes (MDS) Novartis (NVS; SWX:NOVN) FDA approves an expanded label…
  • Millennium M&A comps

    BioCentury on BioBusiness, Finance
    …would value the company at $4.7 billion. (A) Novartis initially bid for Chiron in September 2005; the premium…2B in cash 2006 (A) Novartis Chiron $36.44 $48.00…
  • TB pipeline

    BioCentury on BioBusiness, Strategy
    …in discussions for a number of other projects. NITD= Novartis Institute for Tropical Diseases; KRICT= Korea Research Institute of…PA-824 nitroimidazole Chiron (subsidiary of Novartis) Ph I Nitroimidazole…
  • BioCentury on BioBusiness, Tools & Techniques
    …the Tokyo Metropolitan Institute for Neuroscience and Novartis AG have published a nonviral amyloid beta…to collaborate scientifically on the vaccine with Novartis (NVS; SWX:NOVN, Basel, Switzerland), but since…
  • BioCentury on BioBusiness, Strategy
    …Chiron Corp., now a subsidiary of Novartis AG. PA-824 has shown bactericidal…tuberculosis. The Novartis Institute for Tropical Diseases in Singapore…study. Novartis (NVS; SWX:NOVN, Basel, Switzerland) has…
  • BioCentury on BioBusiness, Strategy
    …Strategy: Infectious out-sourcing Infectious space at Novartis Novartis infectious disease pipeline distributed…sourcing Infectious space at Novartis Novartis infectious disease pipeline distributed across four categories: hepatitis, common hospital…
  • BioCentury on BioBusiness, Strategy
    …editor Infectious space at Novartis NovartisNovartis AG has once again turned…latest in a series by Novartis (NVS; SWX:NOVN, Basel, Switzerland…
  • BioCentury on BioBusiness, Cover Story
    …Partners AG; Wellcome Trust; Global Life Science Ventures; Novartis Venture Fund Azur Ireland $48…Biosciences Partners; 3i Group; Carnegie Asset Management; Novartis Venture Fund; Varuma; GIMV; Clariden Bank; Dow…
  • BioCentury on BioBusiness, Finance
    …Partners AG; Wellcome Trust; Global Life Science Ventures; Novartis Venture Fund Azur Ireland $48…Biosciences Partners; 3i Group; Carnegie Asset Management; Novartis Venture Fund; Varuma; GIMV; Clariden Bank; Dow…
  • BioCentury on BioBusiness, Tools & Techniques
    …companies. - Christopher Maggos Company Product Indication Status Novartis Certican everolimus Transplantation Mkt in EU; FDA…Ph III; submit NDA in 2006/07 Novartis RAD001 Solid tumors; tuberous sclerosis Ph II…
  • BioCentury on BioBusiness, Tools & Techniques
    …Oriented Synthesis chemistry platform, and Novartis AG last week entered a…have been independently confirmed by Novartis," Holtzman said. "With the exception…two years. Along with milestones, Novartis (SWX:NOVN; NVS, Basel, Switzerland…
  • BioCentury on BioBusiness, Regulation
    …reject a patent application from Novartis AG for Gleevec imatinib highlights…property environment. The case - which Novartis has the right to appeal…EMR for Gleevec, granted to Novartis (NVS; SWX:NOVN, Basel, Switzerland…
  • BioCentury on BioBusiness, Tools & Techniques
    Novartis AG (NVS; SWX:NOVN, Basel…is no stranger to pleuromutilins. Novartis Animal Health Inc. has been…Global Life Sciences Ventures; and the Novartis Venture Fund. Sandoz will have a…
  • BioCentury on BioBusiness, Finance
    …Flow In and out at Novartis Venture Novartis…Venture Novartis Venture Fund last week released its…or restarted: Axxima, Therastrat and Vegetech. Novartis Venture also announced that it set…
  • EPS watch

    BioCentury on BioBusiness, Finance
    …negative and flat earnings growth from Pfizer (PFE) and Novartis (NVS; SWX:NOVN), respectively, illustrated why many bigcap healthcare…of about $3B. Novartis (NVS; SWX:NOVN) NA $0.58…
  • PTH pipeline

    BioCentury on BioBusiness, Product Discovery & Development
    …PTH) therapeutics in development and on the market. (A) Novartis has option to use Emisphere's eligen technology with…Oral Osteoporosis Ph I Novartis (A) PTH 1-34 Ipsen…
  • Upcoming milestones

    BioCentury on BioBusiness, Cover Story
    …2006 Genentech (DNA)/Novartis Lucentis…Idenix (IDIX)/Novartis (NVS; SWX:NOVN) …Novartis (NVS; SWX:NOVN) …
  • Upcoming milestones

    BioCentury on BioBusiness, Finance
    …2006 Genentech (DNA)/Novartis Lucentis…Idenix (IDIX)/Novartis (NVS; SWX:NOVN) …Novartis (NVS; SWX:NOVN) …
  • New products to watch

    BioCentury on BioBusiness, Cover Story
    …chromosomal deletion U.S. Celgene (CELG)/Novartis (NVS; SWX:NOVN) Focalin XR Attention deficit…approved in U.S.) Genentech (DNA)/Tanox (TNOX)/ Novartis (NVS; SWX:NOVN) Xolair Allergic asthma EU…
  • New products to watch

    BioCentury on BioBusiness, Finance
    …chromosomal deletion U.S. Celgene (CELG)/Novartis (NVS; SWX:NOVN) Focalin XR Attention deficit…approved in U.S.) Genentech (DNA)/Tanox (TNOX)/ Novartis (NVS; SWX:NOVN) Xolair Allergic asthma EU…
  • BioCentury on BioBusiness, Product Discovery & Development
    …FMS-like tyrosine kinase 3 (FLT-3) inhibitor may do for acute myelogenous leukemia what Novartis AG's Gleevec imatinib Bcr-Abl tyrosine kinase inhibitor did for chronic myelogenous leukemia…
  • CDK inhibitor pipeline

    BioCentury on BioBusiness, Strategy
    …Advanced or refractory solid tumors Ph I Novartis AstraZeneca AZD5438 CDK2 Advanced solid tumors Ph…I Astex AT9311 CDK1 & CDK2 Cancer Preclin Novartis Cyclacel CDK inhibitors ND Inflammatory kidney diseases…
  • BioCentury on BioBusiness, Strategy
    …Ltd. says last week's deal with Novartis AG for two CDK inhibitors for cancer…the deal, Astex (Cambridge, U.K.) granted Novartis (NVS; SWX:NOVN, Basel, Switzerland) a worldwide…
  • BioCentury on BioBusiness, Emerging Company Profiles
    …was validated through INSERM's collaboration with Novartis over several years. During the collaboration, they…expression cloning, while performing research funded by Novartis AG (NVS; SWX:NOVN, Basel, Switzerland) at…
  • 4Q milestones

    BioCentury on BioBusiness, Finance
    …MAA approval Genentech (DNA)/Novartis(NVS; SWX:NOVN) Lucentis ranibizumab…Submit BLA Idenix (IDIX)/Novartis (NVS; SWX:NOVN) Telbivudine (LdT…ADHD) Submit NDA Novartis (NVS; SWX:NOVN) Exjade deferasirox Chronic…
  • BioCentury on BioBusiness, Product Discovery & Development
    …Product Development Novartis: Time is on our side Novartis AG…our side Novartis AG's vildagliptin (LAF237) may have missed…beta cells. Novartis (NVS; SWX:NOVN, Basel, Switzerland) expects that…
  • BioCentury on BioBusiness, Strategy
    …potential to reach blockbuster scale, Novartis AG's strategic collaboration to…Novartis (NVS; SWX:NOVN, Basel, Switzerland…Fishman is president of the Novartis Institutes for BioMedical Research (NIBR…
  • BioCentury on BioBusiness, Strategy
    …Strategy: Novartis loads up …Novartis infectious disease deals …infectious disease-related deals by Novartis (NVS; SWX:NOVN) since the…
  • BioCentury on BioBusiness, Strategy
    …Strategy: Novartis loads up Novartis-Chiron…loads up Novartis-Chiron infectious disease pipeline Novartis' bid…disease pipeline Novartis' bid to acquire Chiron would add eight…
  • BioCentury on BioBusiness, Strategy
    Novartis loads up …Novartis-Chiron infectious disease pipeline Novartis infectious disease deals …have had enough. They asked Novartis AG (NVS; SWX:NOVN, Basel…
  • BioCentury on BioBusiness, Strategy
    Novartis Loads Up A long engagement Chiron…equity, as well as providing a debt guarantee of $425 million. Novartis AG (NVS; SWX:NOVN, Basel, Switzerland), which was formed through the…
  • Ebb & Flow Focus

    BioCentury on BioBusiness, Finance
    …Basel, Switzerland), private investors hold about 43%, Novartis Venture fund and DSM Venture together own…stage renal disease. SPP100 is partnered with Novartis AG (NVS; SWX:NOVN, Basel, Switzerland). Speedel…
  • Tallying TLRs

    BioCentury on BioBusiness, Cover Story
    …Ph I/II ANA975 Novartis Oral prodrug of isatoribine…HBV Ph I ANA971 Novartis Oral prodrug of isatoribine…agonist Cancer Ph II HBY2093 Novartis TLR9 agonist Asthma and allergy…
  • Tallying TLRs

    BioCentury on BioBusiness, Tools & Techniques
    …Ph I/II ANA975 Novartis Oral prodrug of isatoribine…HBV Ph I ANA971 Novartis Oral prodrug of isatoribine…agonist Cancer Ph II HBY2093 Novartis TLR9 agonist Asthma and allergy…
  • BioCentury on BioBusiness, Cover Story
    …CML) 12/20/02 Novartis PFS (ITT): 97.2…GIST) 2/1/02 Novartis PR: 38% Not yet…alpha therapy 5/10/01 Novartis Hematologic response (chronic phase): 88…
  • BioCentury on BioBusiness, Product Discovery & Development
    …CML) 12/20/02 Novartis PFS (ITT): 97.2…GIST) 2/1/02 Novartis PR: 38% Not yet…alpha therapy 5/10/01 Novartis Hematologic response (chronic phase): 88…
  • BioCentury on BioBusiness, Product Discovery & Development
    …variety of diseases outside of oncology. While Novartis AG continues to work on expanding Gleevec…the protein. Gleevec also is marketed by Novartis (NVS; SWX:NOVN, Basel, Switzerland) for CML…
  • Upcoming milestones

    BioCentury on BioBusiness, Finance
    …virus File BLA year end 05 Idenix/Novartis Telbivudine Hepatitis B virus (HBV) Submit…disorder (ADHD) Submit NDA year end 05 Speedel/Novartis Aliskiren (SPP100 ) Hypertension Ph III data 3Q05…
  • BioCentury on BioBusiness, Product Discovery & Development
    …pharma players, are playing catch up to Novartis AG in the renin inhibitor space. Vitae…effects on other organs and morbidity/mortality. Novartis (NVS; SWX:NOVN, Basel, Switzerland) is the…
  • BioCentury on BioBusiness, Cover Story
    …field - Merck & Co. Inc. and Novartis AG - presented Phase II data…of diabetes research at the Novartis Institutes for Biomedical Research, DPP…mimetics. Novartis (NVS; SWX:NOVN, Basel, Switzerland) and…
  • BioCentury on BioBusiness, Product Discovery & Development
    …field - Merck & Co. Inc. and Novartis AG - presented Phase II data…of diabetes research at the Novartis Institutes for Biomedical Research, DPP…mimetics. Novartis (NVS; SWX:NOVN, Basel, Switzerland) and…
  • BioCentury on BioBusiness, Strategy
    …and virus-host cell interactions. Novartis AG added a second leg…Under the deal with ANDS, Novartis (NVS; SWX:NOVN, Basel, Switzerland…compounds are synergistic, so what Novartis is doing makes complete sense…
  • BioCentury on BioBusiness, Tools & Techniques
    …partnering front. Myogen Inc. and Novartis AG are taking HDAC inhibitors…original deal, Myogen (MYOG) and Novartis (NVS; SWX:NOVN) unit Novartis Institutes for BioMedical Research Inc…own. However, Freytag noted that "Novartis has a whole array of…
  • BioCentury on BioBusiness, Analyst Picks & Changes
    …46 after Lucentis from Genentech (DNA) and Novartis (NVS; SWX:NOVN) met the primary endpoint…data (see Eyetech above). QLT's partner Novartis (NVS; SWX:NOVN) markets QLT's Visudyne…
  • Ebb & Flow

    BioCentury on BioBusiness, Finance
    …of Visudyne profits from partner Novartis (NVS; SWX:NOVN). Thus, if…CMEA Ventures; GBS Venture; and Novartis BioVenture Fund. …Investors; Lakeview; Viterbi Group; Sanderling; Novartis BioVentures; Research Corp. Technologies; and…
  • BioCentury on BioBusiness, Tools & Techniques
    …announced a deal to combine its MIF efforts with Novartis AG. Gerald Yakatan, president and…bowel disease (IBD). Last week, Novartis (NVS; SWX:NOVN, Basel, Switzerland) signed a deal…
  • Moving up the ladder

    BioCentury on BioBusiness, Finance
    …136) GlaxoSmithKline ($102) Novartis ($111) Novartis ($124) sanofi…Novartis ($111) Novartis ($124) sanofi-aventis…124.3) (A) Novartis ($89) Merck ($100) sanofi…
  • BioCentury on BioBusiness, Tools & Techniques
    …is widely cytotoxic. Researchers at Novartis AG now report that a…Researchers at the Novartis Institutes for BioMedical Research and…in a variety of indications. Novartis (NVS; SWX:NOVN, Basel, Switzerland…
  • BioCentury on BioBusiness, Product Discovery & Development
    …Senior Writer Although PTK/ZK (PTK787) from Novartis AG and Schering AG recently missed the…Schering (FSE:SCH; SHR, Berlin, Germany) and Novartis (NVS; SWX:NOVN, Basel, Switzerland).…
  • HBV landscape

    BioCentury on BioBusiness, Cover Story
    …from Gilead (GILD); and telbivudine from Idenix (IDIX) and Novartis (NVS; SWX:NOVN). The nucleotides include Hepsera adefovir, which…Nucleoside analog FDA review Idenix/Novartis Telbivudine Nucleoside analog Ph…
  • HBV landscape

    BioCentury on BioBusiness, Product Discovery & Development
    …from Gilead (GILD); and telbivudine from Idenix (IDIX) and Novartis (NVS; SWX:NOVN). The nucleotides include Hepsera adefovir, which…Nucleoside analog FDA review Idenix/Novartis Telbivudine Nucleoside analog Ph…
  • The ADHD crowd

    BioCentury on BioBusiness, Cover Story
    …release methylphenidate Mkt Novartis/Celgene Focalin Short-acting…dexmethylphenidate Mkt Novartis/Celgene/Elan Ritalin LA…methylphenidate Mkt Novartis Ritalin, Ritalin…
  • The ADHD crowd

    BioCentury on BioBusiness, Strategy
    …release methylphenidate Mkt Novartis/Celgene Focalin Short-acting…dexmethylphenidate Mkt Novartis/Celgene/Elan Ritalin LA…methylphenidate Mkt Novartis Ritalin, Ritalin…
  • BioCentury on BioBusiness, Product Discovery & Development
    …of Phase II trials for Novartis AG, which is conducting Phase…Speedel, Novartis and others think that better…of 2005. In the meantime, Novartis (SWX:NOVN; NVS, Basel, Switzerland…
  • BioCentury on BioBusiness, Product Discovery & Development
    …Renin inhibitor pipeline Novartis AG thinks its oral Aliskiren renin inhibitor for…Shannon, global head of clinical R&D at Novartis (SWX:NOVN; NVS, Basel, Switzerland). "But there are…
  • Chasing GI motility

    BioCentury on BioBusiness, Product Discovery & Development
    …line behind marketed serotonin receptor modulators Zelnorm tegaserod from Novartis AG (NVS; SWX:NOVN, Basel, Switzerland) and Lotronex alosetron…Status Mechanism Zelnorm/Zelmac tegaserod Novartis Irritable bowel syndrome(IBS), constipation…
  • BioCentury on BioBusiness, Product Discovery & Development
    …for chronic myelogenous leukemia - one from Novartis AG and the other from Bristol…S. in May 2001 by Novartis (NVS; SWX:NOVN, Basel, Switzerland…data. Novartis follows on In…
  • BioCentury on BioBusiness, Product Discovery & Development
    …therapy 5/10/01 Novartis 3 (1,027) Gleevec…GIST) 2/1/02 Novartis 1 (147) Gleevec imatinib…Ph+ CML 12/20/02 Novartis 1 (1,106) Mylotarg gemtuzumab…
  • EPS watch

    BioCentury on BioBusiness, Finance
    …2.59-$2.64. Novartis (NVS; SWX:NOVN) NA $0.63 NA…growth reflects strong sales of Visudyne with partner Novartis (NVS; SWX:NOVN). The AMD drug posted 3Q04…
  • Rapamycin pipeline

    BioCentury on BioBusiness, Tools & Techniques
    …Indication Status Johnson & Johnson Cypher Restenosis Mkt Novartis Certican (RAD001) Transplantation Mkt in EU; Approvable…779) Renal cell carcinoma(RCC) Ph III Novartis RAD001 Solid tumors Ph II Ariad AP23573…
  • BioCentury on BioBusiness, Politics and Policy
    …drugs, but it recently deferred action on Novartis AG's attempt to use the provision…obtain approval for Omnitrop, a generic hGH. Novartis (NVS; SWX:NOVN, Basel, Switzerland) is a…
  • BioCentury on BioBusiness, Strategy
    …Strategy Busy Novartis By…The research arm of Novartis AG has done more than…in a specific hole in Novartis' pathway analysis capability, while giving…
  • AMD pipeline

    BioCentury on BioBusiness, Cover Story
    …Indication Status (Milestone) Mechanism of action QLT/Novartis Visudyne Predominantly classic choroidal neovascularization (CNV…metalloproteinases (MMPs) and inhibits endothelial cell migration Genentech/Novartis Lucentis Minimally classic or occult CNV in…
  • AMD pipeline

    BioCentury on BioBusiness, Product Discovery & Development
    …Indication Status (Milestone) Mechanism of action QLT/Novartis Visudyne Predominantly classic choroidal neovascularization (CNV…metalloproteinases (MMPs) and inhibits endothelial cell migration Genentech/Novartis Lucentis Minimally classic or occult CNV in…
  • An Indian pipeline

    BioCentury on BioBusiness, Cover Story
    …agonist Type II diabetes Preclin Novartis discontinued development; Dr. Reddy's evaluating DRF 11057 oxazolidinone molecule…breaker Heart disease Preclin Novartis has option to acquire exclusive global rights TRC-303…
  • BioCentury on BioBusiness, Cover Story
    …Inc. (PFE, New York, N.Y.) and Novartis AG (NVS; SWX:NOVN, Basel, Switzerland) already…We had the option of waiting for Novartis chemistry resources to break free, or doing…
  • BioCentury on BioBusiness, Product Discovery & Development
    …Staff Writer By any definition, Gleevec imatinib from Novartis AG has been a success as a treatment…of CML. Gleevec, which Novartis (NVS; SWX:NOVN, Basel, Switzerland) markets as…
  • BioCentury on BioBusiness, Politics and Policy
    …Usdin Washington Editor Novartis AG has fired back against rival Pfizer Inc…and Cosmetic Act. Sandoz, the generics subsidiary of Novartis (NVS; SWX:NOVN, Basel, Switzerland), has filed an…
  • BioCentury on BioBusiness, Strategy
    …compound was discovered in collaboration with Novartis AG (NVS, SWX:NOVN, Basel, Switzerland…2Q05) Novartis Metastatic…2Q06) Novartis Glioblastoma…
  • What's covered

    BioCentury on BioBusiness, Politics and Policy
    …2-4 Femara fetrozole Novartis Breast cancer stages 2…2-4 Gleevec imatinib Novartis Gastrointestinal stromal tumor (GIST…Miacalcin salmon calcitonin nasal spray Novartis Osteoporosis (A) Pegasys peginterferon alfa…
  • Not just skin deep

    BioCentury on BioBusiness, Strategy
    …Age-related macular degeneration (AMD) Mkt QLT Novartis Eligard leuprolide 1-, 3- and 4-month…Visudyne Minimally classic AMD Ph III QLT Novartis QLT0074 lemuteporphin Androgenetic alopecia Ph II QLT…
  • BioCentury on BioBusiness, Strategy
    …the Sandoz Inc. generic pharmaceuticals unit of Novartis AG (NVS; SWX:NOVN, Basel, Switzerland). The…second manufacturing site under our deal with Novartis, and this would provide that or at…
  • Moonlighting at NIH

    BioCentury on BioBusiness, Politics and Policy
    …Disease Branch $198,940 + stock Eli Lilly; Novartis; Pfizer; AstraZeneca; Lipid Sciences Consultant; advisory board member Michael…NIAID - Laboratory Chief $426,400 Suntory; Novartis Director Mahendra Rao NIA - Section…
  • BioCentury on BioBusiness, Politics and Policy
    …petitions also specifically ask FDA to reject Novartis AG’s application for approval of Omnitrop…Calif.), PFE (New York, N.Y.) and Novartis (NVS; SWX:NOVN, Basel, Switzerland). All three…
  • BioCentury on BioBusiness, Strategy
    Novartis finds its gold standard …in the clinic through partnerships, Novartis AG has a vested interest…therapeutic antibodies against targets specified by Novartis (NVS; SWX: NOVN, Basel, Switzerland). MorphoSys…
  • BioCentury on BioBusiness, Politics and Policy
    …Pfizer attacks Novartis on biogenerics …New information about Novartis AG's efforts to persuade…filed for Omnitrop somatropin by Novartis subsidiaries Biochemie U.S. Inc…
  • BioCentury on BioBusiness, Cover Story
    …Speedel Switzerland $57.6 Novartis; DSM Venturing Intercell Austria $50.0…33.4 Burrill & Co.; 3i; DVC Deutsche Venture Capital; Novartis Venture Fund; CAPEXIT; gamma capital partners; Horizonte Venture Fund…
  • BioCentury on BioBusiness, Finance
    …Speedel Switzerland $57.6 Novartis; DSM Venturing Intercell Austria $50.0…33.4 Burrill & Co.; 3i; DVC Deutsche Venture Capital; Novartis Venture Fund; CAPEXIT; gamma capital partners; Horizonte Venture Fund…
  • All that Jazz . .

    BioCentury on BioBusiness, Strategy
    …Prospect Venture Partners; Vulcan Ventures; HBM BioVentures; Novartis; Wellcome Trust; Tallwood Venture Capital; Lotus BioScience…Investors; Foundation Medical Partners; Adams Street Partners; Novartis; Global Life Science Partners; Posco BioVentures; Private…
  • BioCentury on BioBusiness, Politics and Policy
    …Wess Senior editors Novartis AG's goal of having the first follow…wrong last winter. The regulatory glitch apparently took Novartis (NVS; SWX:NOVN, Basel, Switzerland) by surprise. But…
  • 'A' for effort

    BioCentury on BioBusiness, Finance
    …Sciences; CMEA Ventures; Lombard Odier; Novartis; Aravis Ventures; Alejandro Zaffaroni; Singapore…Spun out of Novartis Research Foundation's Genomics Institute…Capital; CM Capital; CMEA Ventures; Novartis; Rothschild; Versant Ventures …
  • BioCentury on BioBusiness, Cover Story
    …Complete response letter 6/9/03 Novartis Lumiracoxib Osteoarthritis and pain Non-approvable…rejection Approvable letter 10/27/03 Novartis, SkyePharma, Schering-Plough Foradil Asthma Approvable letter 10/27…
  • BioCentury on BioBusiness, Regulation
    …Complete response letter 6/9/03 Novartis Lumiracoxib Osteoarthritis and pain Non-approvable…rejection Approvable letter 10/27/03 Novartis, SkyePharma, Schering-Plough Foradil Asthma Approvable letter 10/27…
  • BioCentury on BioBusiness, Strategy
    …its 2000 kinase deal with Novartis AG. Following last week's…May 15, 2000). As amended, Novartis will be responsible for compounds…dedicated to the deal with Novartis (NVS; SWX:NOVN, Basel, Switzerland…
  • Ebb & Flow

    BioCentury on BioBusiness, Finance
    Ebb & Flow Striking while the iron's hot By Eric Pierce & Shaun Brown Mature money Mixed grill Money Raised in 2004 With follow-on paper pricing left and right, the griddle is getting fairly hot. Last week, $…
  • Upcoming milestones

    BioCentury on BioBusiness, Cover Story
    …due to AMD Ph III Results 3Q04 Novartis Minimally classic CNV due to AMD Ph…to AMD Ph III Complete enrollment 3Q04 Novartis Sepracor Xopenex Asthma Ph III Submit NDA…
  • Upcoming milestones

    BioCentury on BioBusiness, Finance
    …due to AMD Ph III Results 3Q04 Novartis Minimally classic CNV due to AMD Ph…to AMD Ph III Complete enrollment 3Q04 Novartis Sepracor Xopenex Asthma Ph III Submit NDA…
  • BioCentury on BioBusiness, Emerging Company Profiles
    …Polymeropoulos, who was head of pharmacogenetics at Novartis AG (SWX:NOVN; NVS, Basel, Switzerland). "Working…idea doesn't work," Polymeropoulos said. "Joining Novartis as a founder of the pharmacogenetics department…
  • Vertex pipeline

    BioCentury on BioBusiness, Product Discovery & Development
    …Preclinical Cancer Aurora kinases Novartis VX-608 Preclinical Stroke…kinase 3beta (GSK-3beta) Novartis VX-680 Preclinical Cancer…Cancer Aurora kinases, FLT-3 Novartis VX-799 Preclinical Sepsis Caspases…
  • BioCentury on BioBusiness, Strategy
    …latest deal, to be announced today, the Novartis Institutes for BioMedical Research Inc. will have…II diabetes. The institute is part of Novartis AG (NVS; SWX:NOVN, Basel, Switzerland). The…
  • Trapping value

    BioCentury on BioBusiness, Strategy
    …REGN portion will be covered by two loans from Novartis. The first will cover REGN's portion of 2003…Eyetech/ Pfizer Regeneron/ Aventis Regeneron/ Novartis Compound Macugen VEGF- binding…
  • Corporate Profile

    BioCentury on BioBusiness, Emerging Company Profiles
    …and Helmut Eckert Corporate partners: Protein Design Labs, Novartis, BioInvent, Diomeda, Glycart, Immunicon University collaborators: The…7 million) Investors: 3i Austria; Novartis Venture Fund; and Deutsche Venture Capital DVC…
  • BioCentury on BioBusiness, Emerging Company Profiles
    …by former managers of R&D at Novartis AG (SWX:NOVN; NVS, Basel, Switzerland). The…have also seen excellent tolerance back at Novartis. Currently, we are trying a novel application…
  • BioCentury on BioBusiness, Finance
    …cell activation Autoimmune Novartis NA Bronchitis NovartisNovartis NA Bronchitis Novartis Inhibition of tumor…tumor angiogenesis Cancer Novartis T cell activation…
  • BioCentury on BioBusiness, Finance
    …did with Pfizer and Idenix completed with Novartis," said MPM's Nick Simon. Last year…Dec. 23, 2002). And earlier this year, Novartis AG (NVS; SWX:NOVN, Basel, Switzerland) agreed…
  • BioCentury on BioBusiness, Finance
    …or clinical delays (Genzyme's post-marketing Renagel trial). Novartis (SWX:NOVN; NVS) also reported earnings last week, reported…Growing Anemic?" AX). Novartis (SWX:NOVN; NVS) NA $ 0.43…
  • BioCentury on BioBusiness, Cover Story
    …week's deal in which Novartis AG obtained a 51% stake…addition to payments to shareholders, Novartis (NVS; SWX:NOVN, Basel, Switzerland…Jean-Pierre Sommadossi argued that "Novartis has an incentive to keep…
  • BioCentury on BioBusiness, Finance
    …week's deal in which Novartis AG obtained a 51% stake…addition to payments to shareholders, Novartis (NVS; SWX:NOVN, Basel, Switzerland…Jean-Pierre Sommadossi argued that "Novartis has an incentive to keep…
  • BioCentury on BioBusiness, Tools & Techniques
    …Amevive alefacept LFA-3 fusion protein Mkt Novartis Neoral cyclosporine Calcineurin inhibitor Mkt Genentech Raptiva…Siplizumab Anti-CD2 antibody Ph II BioTransplant Novartis Elidel pimecrolimus Calcineurin inhibitor Ph II QuatRx…
  • BioCentury on BioBusiness, Cover Story
    …Companies like AstraZeneca plc, Novartis AG, Merck & Co. Inc., Pfizer…Whitehouse Station, N.J.) and Novartis (NVS, Basel, Switzerland) have already…Indeed, even though Novartis established its beachhead in San…
  • AMD results

    BioCentury on BioBusiness, Product Discovery & Development
    …40% on placebo (p=0.0189). QLT/ Novartis Visudyne 2 Ph III Classic-containing…15% for Visudyne vs. 36% for placebo). QLT/ Novartis Visudyne Ph II 6- month results Minimally…
  • Good batting average

    BioCentury on BioBusiness, Finance
    …it was working through its Renagel inventory issue. Novartis was not treated as kindly, as its $6…digit growth in 2003 Novartis (SWX: NOVN; NVS)(A) $0.44 $0.45…
  • BioCentury on BioBusiness, Product Discovery & Development
    …and complete elimination of tumor Gleevec imatinib Novartis Philadelphia chromosome positive chronic myeloid leukemia in…Overall hematologic & cytogenetic response rates Gleevec imatinib Novartis KIT (CD117) positive unresectable and/or metastatic…
  • BioCentury on BioBusiness, Finance
    …to treat Alzheimer's disease Novartis/Celgene/Elan FDA approves Novartis' Ritalin LA…disease Novartis/Celgene/Elan FDA approves Novartis' Ritalin LA to treat ADHD Repligen FDA approves SecreFlo…
  • BioCentury on BioBusiness, Strategy
    …Strategy Novartis: Tapping into U.S. science By…The decision by Novartis A.G. to move its…Coast. In 1998, NVS established the Novartis Agricultural Discovery Institute at the University…
  • BioCentury on BioBusiness, Strategy
    …Strategy: Novartis: Tapping into U.S. science Global research…Global research landscape Novartis AG's major pharmaceutical research facilities. Facility Location…development 60 scientists Novartis Research Inst. Vienna, Austria Autoimmune…
  • Mature start-ups

    BioCentury on BioBusiness, Cover Story
    …2 $43.0 Spun out of Novartis Research Foundation's Genomics Institute in 2001 to…11 $12.0 Spun out of Novartis's Genomics Institute and the Australian National University…
  • Mature start-ups

    BioCentury on BioBusiness, Strategy
    …2 $43.0 Spun out of Novartis Research Foundation's Genomics Institute in 2001 to…11 $12.0 Spun out of Novartis's Genomics Institute and the Australian National University…
  • BioCentury on BioBusiness, Strategy
    …Undisclosed clinical trials Reliant Lescol/Lescol XL Novartis Cardiovascular Marketed DynaCirc/Dyna Novartis Cardiovascular Marketed…Lescol XL Novartis Cardiovascular Marketed DynaCirc/Dyna Novartis Cardiovascular Marketed Circ CR Axid Eli Lilly…
  • BioCentury on BioBusiness, Strategy
    …publicized attempt to break the cyclosporine franchise of Novartis AG. SANG, which began…an anti-IL-2 receptor antibody marketed by Novartis (NVS; SWX:NOVN, Basel, Switzerland) as an induction…
  • BioCentury on BioBusiness, Tools & Techniques
    …marks new territory Researchers from Novartis AG reinforced the ability of pharmacogenomics to identify…the Breast Cancer Symposium in San Antonio. Novartis (NVS; SWX:NOVN, Basel, Switzerland) received FDA…
  • BioCentury on BioBusiness, Strategy
    …South San Francisco, Calif.) and Novartis AG (NVS; SWX:NOVN, Basel…was developed by TNOX and Novartis predecessor Ciba-Geigy AG under…Judge Patel said, "Genentech and Novartis are wrong." According to the…
  • BioCentury on BioBusiness, Tools & Techniques
    …the mechanisms of resistance to Novartis AG's recently approved Gleevec…patients would relapse on Gleevec, Novartis itself has seen resistance mechanisms…clinical development for oncology at Novartis (NVS; SWX: NOVN, Basel, Switzerland…
  • Corporate Profile

    BioCentury on BioBusiness, Emerging Company Profiles
    …Hans Eppenberger Corporate partners: Antibioticos, GlaxoSmithKline, Novartis, Novo Nordisk and Solidago University collaborators…39.5 million Investors: Global Life Science; Innoventure; Novartis Venture Fund; Lombard Odier; Alta Partners; Aventic; Health…
  • BioCentury on BioBusiness, Finance
    …its 20% voting share in ROCZ to Novartis AG (NVS; SWX:NOVN) (see BioCentury, May…recent ouster in the wake of the Novartis deal, is still a limited partner at…
  • BioCentury on BioBusiness, Tools & Techniques
    …Phase II data on a new indication for Novartis AG's Gleevec, presented at the American Society…in GIST. Researchers at Novartis (SWX:NVS; NOVN, Basel, Switzerland) thus hypothesized…
  • BioCentury on BioBusiness, Finance
    …some hot gossip. Novartis AG's decision last week to lay out…But both companies are taking the position that Novartis (NVS; SWX:NOVN) is a long-term financial…
  • BioCentury on BioBusiness, Tools & Techniques
    …Celgene Corp., which signed a deal with Novartis AG last week, believes its functional genomics…candidates. Celgene (CELG, Warren, N.J.) and Novartis (NVS; SWX:NOVN, Basel, Switzerland) plan to…
  • BioCentury on BioBusiness, Tools & Techniques
    …Even though Novartis A.G. discovered its Glivec…leukemia in mid-1998, and Novartis plans to file for FDA…patients with chronic stage CML, Novartis (SWX:NOVN; NVS, Basel, Switzerland…
  • ADHD products

    BioCentury on BioBusiness, Cover Story
    …Product Description and mechanism Status Partner Novartis (SWX:NOVN; NVS) Ritalin methylphenidate Central nervous system stimulant…more potent than l-enantiomer III Biovail, Novartis Eli Lilly (LLY) Somerset Tomoxetine Selegiline…
  • ADHD products

    BioCentury on BioBusiness, Strategy
    …Product Description and mechanism Status Partner Novartis (SWX:NOVN; NVS) Ritalin methylphenidate Central nervous system stimulant…more potent than l-enantiomer III Biovail, Novartis Eli Lilly (LLY) Somerset Tomoxetine Selegiline…
  • BioCentury on BioBusiness, Cover Story
    …with products to take on Novartis AG's Ritalin and Ritalin…market, which include Ritalin from Novartis (SWX:NOVN, Basel, Switzerland), Methylin…The product is partnered with Novartis (see BioCentury, May 1). …
  • BioCentury on BioBusiness, Politics and Policy
    …YieldGard or KnockOut varieties from Novartis Seeds Inc. (Golden Valley, Minn…particular, Giddings argued that the Novartis Bt corn varieties are planted…conspiring to help the environment. Novartis already has cut back marketing…
  • BioCentury on BioBusiness, Strategy
    …with products to take on Novartis AG's Ritalin and Ritalin…market, which include Ritalin from Novartis (SWX:NOVN, Basel, Switzerland), Methylin…The product is partnered with Novartis (see BioCentury, May 1). …
  • BioCentury on BioBusiness, Tools & Techniques
    …Genetic Therapy Inc. subsidiary of Novartis Pharma AG (NVS; SWX:NOVN…yet clear how problematic the Novartis finding will be when xenotransplantation…Indeed, Novartis already plans to provide more…
  • BioCentury on BioBusiness, Product Discovery & Development
    …sure whether the product would show bioequivalence to Novartis AG's Sandimmune cyclosporine or second generation product…that of SangCya." Novartis (SWX:NOVN; NVS, Basel, Switzerland) suggested that the…
  • BioCentury on BioBusiness, Cover Story
    Novartis takes hands off approach …OXFORD - Novartis Pharma AG is looking hard…of global R&D at Novartis (SWX:NOVN, Basel, Switzerland). "I…
  • BioCentury on BioBusiness, Cover Story
    …in development Kinase Land Grab: Novartis takes hands off approach …s eight-compound deal between Novartis Pharma AG and Vertex Pharmaceuticals…phase of our agreement with Novartis begins," Boger told BioCentury. "…
  • BioCentury on BioBusiness, Emerging Company Profiles
    …before its merger with Sandoz to form Novartis. Karn discovered that inhibiting the protein could…prevent HIV replication. Following the formation of Novartis, the project ground to a halt, but…
  • BioCentury on BioBusiness, Tools & Techniques
    …bunch of these targets with Novartis," Tally said. CBST last year…licensed the technology to partner Novartis Pharma AG (SMI:NOVN, Basel…validated targets per year to Novartis," he said. …
  • BioCentury on BioBusiness, Tools & Techniques
    …at the previous ASH, there was the Novartis product - after that, a lot of attention…that did generate excitement at ASH was Novartis Pharmaceuticals Corp.'s STI-571 oral inhibitor…
  • BioCentury on BioBusiness, Strategy
    …Last week's decision by Novartis AG and AstraZeneca plc to…Similarly Novartis Chairman and CEO Daniel Vasella…companies, the futures of both Novartis and AstraZeneca are not so…
  • BioCentury on BioBusiness, Emerging Company Profiles
    …and Sandoz merged to form Novartis, the new company set up…the new company set up Novartis Venture Fund to cushion the…deals with Bayer, Boehringer Ingelheim, Novartis Pharma and Schering, together with…
  • GeneData AG

    BioCentury on BioBusiness, Emerging Company Profiles
    …Boehringer Ingelheim, Byk Gulden, Hoechst Marion Roussel, Novartis Agro, Novartis Pharma, and Schering University collaborators: None Number…employees: 20 Funds raised: NA Investors: Novartis Venture Fund CEO: Othmar Pfannes Patents…
  • BioCentury on BioBusiness, Politics and Policy
    …public comment periods. Monsanto, Novartis Ag, and other biotech companies contacted by BioCentury…where we tore up crops grown by the Novartis grant recipient). We want to stress that you…
  • BioCentury on BioBusiness, Politics and Policy
    …companies like Monsanto Co. (St. Louis, Mo.), Novartis Group (Basel, Switzerland) and AgrEvo GmbH (Berlin…backed up by Stephen Smith, CEO of Novartis Seeds Ltd. U.K., who said that…
  • BioCentury on BioBusiness, Cover Story
    …knuckled What Novartis did By…WASHINGTON - Although Novartis Consumer Health denied reports last…because of safety concerns - other Novartis companies produce and distribute genetically…
  • BioCentury on BioBusiness, Cover Story
    …Bare-knuckled: What Novartis did Bare-knuckled: Loss of…acknowledges do not yet exist, Novartis Consumer Health has decided to…in its baby food lines, Novartis has decided to respond to…
  • BioCentury on BioBusiness, Cover Story
    …intention of revoking corn permits issued to Novartis and Monsanto, Peter Jorgensen, spokesperson for acting…that Austria and Luxembourg already have banned Novartis' Bt maize, Breyer said "the other member…
  • BioCentury on BioBusiness, Cover Story
    …regulatory and government affairs at Novartis Seeds, whose Bt corn was…Novartis' Lottstein also noted that the…monarch larvae that fed on a Novartis Bt-hybrid to pollen from an…
  • BioCentury on BioBusiness, Strategy
    …up some marketing muscle against Novartis Pharmaceutical Corp. for its SangCya…able to compete effectively with Novartis, which markets Neoral liquid and…a strong counter-push from Novartis (East Hanover, N.J.). …
  • BioCentury on BioBusiness, Tools & Techniques
    …CEO of Avant Immunotherapeutics Inc. (AVAN, Needham, Mass.). Novartis Pharma AG (Basel, Switzerland) has an option to…the Imutran Ltd. unit (Cambridge, U.K.) of Novartis Pharma. Independent efforts are…
  • BioCentury on BioBusiness, Strategy
    …to protect its cyclosporine franchise, Novartis Pharmaceuticals Corp. sued SangStat Medical…that SANG's SangCya infringes Novartis' U.S. Patent No. 5…Novartis also took aim at the…
  • BioCentury on BioBusiness, Tools & Techniques
    …by a researcher at partner Novartis that, fortunately, caused no lasting…kg originally reported by the Novartis researcher. The higher dose still…to light last year after Novartis (Basel, Switzerland) discovered that one…
  • BioCentury on BioBusiness, Tools & Techniques
    …in plants. In its deal with Novartis Agribusiness Biotechnology Research Inc. (Research Triangle Park…for the first four projects identified by Novartis. "The deal is intended to be expandable…
  • BioCentury on BioBusiness, Strategy
    …PDLI, Fremont, Calif.) Zenapax and Novartis Pharma AG's Simulect MAbs…bioequivalence of its capsules to Novartis's Neoral capsules. …company's optimism is that Novartis, which markets the branded cyclosporine…
  • BioCentury on BioBusiness, Cover Story
    …SangStat vs. Novartis …its long-awaited assault against Novartis Pharmaceutical Corp.'s cyclosporine franchise…pitting its SangCya product against Novartis's Sandimmune and newer Neoral…
  • BioCentury on BioBusiness, Tools & Techniques
    …and its partners Tanox Biosystems Inc. and Novartis Pharma AG last week presented positive Phase…medication required. GNE, Tanox (Houston, Texas) and Novartis (Basel, Switzerland) are developing anti-IgE under…
  • BioCentury on BioBusiness, Politics and Policy
    …kilos of corn modified by Novartis AG to resist the European…dangerous, a claim rebutted by Novartis. "More than 30 scientific bodies…that genetically modified maize from Novartis is absolutely harmless and is…
  • BioCentury on BioBusiness, Strategy
    …Del.), Hoechst AG (Frankfurt, Germany), Novartis AG (Basel, Switzerland), and Rhone…For example, the creation of Novartis in 1997 involved similar elements…into pharmaceuticals - something that even Novartis is willing to acknowledge. "People…
  • BioCentury on BioBusiness, Politics and Policy
    …by the Swiss pharma giants Novartis, Roche and Ares Serono, said…Indeed, this exodus has started. Novartis recently announced the formation of…announced the formation of the Novartis Institute for Functional Genomics in…
  • BioCentury on BioBusiness, Tools & Techniques
    …Hoffmann-La Roche Inc., and Novartis Pharmaceuticals Corp.'s Simulect basiliximab…similar (see chart). Nevertheless, both Novartis and PDLI/Roche point to…research for transplant/immunology at Novartis (East Hanover, N.J.), noted…
  • BioCentury on BioBusiness, Cover Story
    Fixing this picture Lance's agenda By Karen Bernstein Editor-in-Chief Market value tracking: Chiron Corp. company profile and pipeline intelligence from BCIQ' href='http://www.biocentury.com/companies/Chiron_Corp'…
  • BioCentury on BioBusiness, Politics and Policy
    …Ward Editor, Europe AgrEvo, Monsanto and Novartis have moved closer to being able to commercialize…processing, but not for cultivation. Similarly, the Novartis Bt-11 corn, modified to have the…
  • BioCentury on BioBusiness, Tools & Techniques
    …Myriad Genetics Inc. and partner Novartis Pharmaceuticals Corp. have discovered a…question of how MYGN and Novartis will exploit the discovery to…Ballinger said that MYGN and Novartis (East Hanover, N.J.) are…
  • BioCentury on BioBusiness, Politics and Policy
    …be EPA regulations." Monsanto, Novartis and other large ag biotech companies with Bt…to Jeff Stein, senior regulatory affairs manager at Novartis Seed (Research Triangle Park, N.C.) because plants…
  • BioCentury on BioBusiness, Politics and Policy
    …applications by AgrEvo, Monsanto and Novartis to market genetically modified corn…committees during the review of Novartis' Bt maize and has decided…committees. Novartis Seeds expressed disappointment that Bjerregaard's…
  • BioCentury on BioBusiness, Strategy
    …and out-licensed Iloperidone to Novartis Pharma AG in a deal…a $5 million milestone from Novartis upon the first submission of…The milestones we receive from Novartis will pass through to Hoechst…
  • BioCentury on BioBusiness, Emerging Company Profiles
    …s first program is a collaboration with Novartis (Basel, Switzerland) to develop small molecules to…in amyotrophic lateral sclerosis (ALS). Idun and Novartis are developing small molecule inhibitors of caspases…
  • BioCentury on BioBusiness, Politics and Policy
    …manager at the industry-backed lobby Interpharma. Novartis and F. Hoffmann-La Roche would have…much of their research activity. Between them, Novartis and Roche invest some Sfr4.3 billion…
  • BioCentury on BioBusiness, Strategy
    …was developed by Japan's Eisai Co. Ltd. Novartis' Exelon rirastigmin is expected to follow in 1998…neurotransmitter is deficient. Novartis' Exelon is a "pseudo-irreversible" inhibitor, with the…
  • BioCentury on BioBusiness, Politics and Policy
    …EPA FDA Latest approval Corn ECB tolerant Novartis Y Y(V) C 1995 Insect tolerant…Y Y(V) C 1995 Insect tolerant Novartis Y Y(V) C 1996 ECB tolerant…
  • BioCentury on BioBusiness, Politics and Policy
    …sale of the biotech corn developed by Novartis AG (Basel, Switzerland). The corn…safety has come at a crucial time for Novartis, which is submitting its Bt corn hybrid for…
  • BioCentury on BioBusiness, Product Discovery & Development
    …whose lab, in collaboration with Ciba (now Novartis Pharma AG, Basel, Switzerland), used a combinatorial…in exchange for a minority equity position. Novartis has since discontinued the HIV project done…
  • BioCentury on BioBusiness, Analyst Picks & Changes
    …Cerestat for stroke and traumatic brain injury. Novartis' Selfotel failed in two Phase III trials…Selfotel failed in two Phase III trials; Novartis/CoCensys' ACEA-1021 caused renal toxicity in…
  • BioCentury on BioBusiness, Politics and Policy
    …accept responsibility. "The technology developers, Monsanto, Novartis and others, sold products to farmers," Conzelmann…Netherlands, which manufactures a genetically modified chicory; Novartis, which manufactures a maize; AgroEvo, which makes…
  • BioCentury on BioBusiness, Strategy
    …How CoCensys plans life after Novartis …do just that after partner Novartis Pharma AG (Basel, Switzerland) said…Ciba-Geigy (now part of Novartis) in 1994 from Acea Pharmaceuticals…
  • BioCentury on BioBusiness, Politics and Policy
    NOVARTIS DEMURS: Novartis denied reports in the New…and other newspapers that its Novartis Seeds unit had become an…engineering. Michael Scott, a Novartis spokesperson, said "there is no change…
  • BioCentury on BioBusiness, Cover Story
    …vehicles, CHIR avoided them as too costly. And finally, while GENZ remains independently owned, partner Novartis holds a 49.9 percent stake in CHIR, an outgrowth of their long-standing…
  • BioCentury on BioBusiness, Regulation
    Novartis and the FTC …Sandoz and Ciba-Geigy into Novartis could reduce competition in gene…to market, the FTC asked Novartis to provide access to the…
  • Novartis and the FTC …Ciba-Geigy and Sandoz into Novartis contingent on the companies' agreement…and in this respect the Novartis decision is nothing new. …
  • BioCentury on BioBusiness, Regulation
    …s seed subsidiary, which will become part of Novartis Seeds as a result of Ciba's merger…the EU scientists. Novartis will target corn growers in Spain, southern France…
  • BioCentury on BioBusiness, Strategy
    …combined company, to be named Novartis, also will have gene mapping…Novartis will have sales of CHF14…percent of the new company. Novartis will have a market capitalization…